BioMedLib Search Engine [ goto HOMEPAGE ]

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Adenoma / surgery. Carcinoid Tumor / surgery. Carcinoma in Situ / surgery. Colonic Polyps / surgery. Colonoscopy / methods. Microsurgery / methods. Rectal Neoplasms / surgery

[MeSH-minor] Aged. Anal Canal. Diagnosis, Differential. Female. Follow-Up Studies. Humans. Male. Neoplasm Recurrence, Local. Retrospective Studies. Treatment Outcome

MedlinePlus Health Information. consumer health - Carcinoid Tumors.

MedlinePlus Health Information. consumer health - Colonic Polyps.

MedlinePlus Health Information. consumer health - Colonoscopy.

COS Scholar Universe. author profiles.

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18481147.001).

[ISSN] 1530-0358

[Journal-full-title] Diseases of the colon and rectum

[ISO-abbreviation] Dis. Colon Rectum

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Involvement of the AP-1 (activator protein-1) transcription factor has been demonstrated previously in the regulation of cell proliferation and cell-cycle progression, in the control of cell migration, invasion and metastasis, and in signal transduction, stress responsiveness, DNA replication and DNA repair.

In the present study, we report that overexpression of a transfected gene encoding YB-1 in human HeLa cervical carcinoma cells significantly represses the transactivation of a minimal AP-1 reporter construct in response to the tumour promoter PMA.

To identify new nuclear proteins that bind specifically to the AP-1 DNA-binding site, we devised a DNA-affinity-chromatography-based assay termed NAPSTER (nucleotide-affinity preincubation specificity test of recognition) and discovered a 49 kDa protein from human cancer cells that binds in a sequence-specific manner to the AP-1 DNA sequence.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

ORBi (University of Liege). Free full Text at ORBi .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Exp Cell Res. 1999 Nov 25;253(1):180-5 [10579922.001]

[Cites] Biochim Biophys Acta. 1999 Dec 23;1489(2-3):263-80 [10673028.001]

[Cites] J Biol Chem. 2000 Aug 18;275(33):25766-73 [10825169.001]

[Cites] Nucleic Acids Res. 2001 Mar 1;29(5):1200-7 [11222770.001]

[Cites] Oncogene. 2001 Apr 30;20(19):2438-52 [11402339.001]

[Cites] J Biol Chem. 2001 Aug 24;276(34):32362-72 [11431474.001]

[Cites] Anal Biochem. 2001 Dec 15;299(2):203-10 [11730344.001]

[Cites] Mol Cell Biol. 2002 Jan;22(2):587-98 [11756554.001]

[Cites] J Leukoc Biol. 2002 Jan;71(1):9-15 [11781376.001]

[Cites] Nat Rev Cancer. 2001 Dec;1(3):181-93 [11902573.001]

[Cites] Lancet Oncol. 2000 Nov;1:181-8 [11905657.001]

[Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]

[Cites] J Biol Chem. 2002 Sep 20;277(38):34967-77 [12087103.001]

[Cites] Gene. 2002 Jul 10;294(1-2):1-12 [12234662.001]

[Cites] Cancer Sci. 2003 Jan;94(1):9-14 [12708467.001]

[Cites] Bioessays. 2003 Jul;25(7):691-8 [12815724.001]

[Cites] J Biol Chem. 2003 Jul 25;278(30):27988-96 [12695516.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):12384-9 [14530393.001]

[Cites] J Biol Chem. 2003 Oct 31;278(44):43470-9 [12917425.001]

[Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]

[Cites] Mol Carcinog. 2004 Jan;39(1):34-60 [14694446.001]

[Cites] Cancer Metastasis Rev. 2004 Jan-Jun;23(1-2):101-17 [15000152.001]

[Cites] Hum Pathol. 2004 Mar;35(3):290-7 [15017584.001]

[Cites] Prostate. 2004 May 15;59(3):337-49 [15042610.001]

[Cites] J Virol. 2004 Jul;78(14):7478-89 [15220421.001]

[Cites] Cell. 1987 Jun 19;49(6):729-39 [3034432.001]

[Cites] Cell. 1987 Jun 19;49(6):741-52 [3034433.001]

[Cites] Cell. 1988 Mar 11;52(5):705-12 [2830989.001]

[Cites] EMBO J. 1989 Jan;8(1):127-32 [2540954.001]

[Cites] Biochem Biophys Res Commun. 1996 May 6;222(1):164-70 [8630063.001]

[Cites] Ann Oncol. 1996 Feb;7(2):129-33 [8777167.001]

[Cites] Cancer Res. 1996 Sep 15;56(18):4224-8 [8797596.001]

[Cites] J Biol Chem. 1996 Nov 22;271(47):30089-95 [8939957.001]

[Cites] Mol Endocrinol. 1998 Jul;12(7):973-85 [9658402.001]

(PMID = 15702969.001).

[ISSN] 1470-8728

[Journal-full-title] The Biochemical journal

[ISO-abbreviation] Biochem. J.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / CA73783; United States / NIEHS NIH HHS / ES / 5 P30 ES09106-03; United States / NCI NIH HHS / CA / R29 CA073783; United States / NIEHS NIH HHS / ES / P30 ES009106; United States / NIEHS NIH HHS / ES / P030ES09106

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / Protein Subunits; 0 / RNA, Messenger; 0 / Transcription Factor AP-1; 0 / Y-Box-Binding Protein 1; 0 / YBX1 protein, human; 9007-49-2 / DNA; EC 3.4.24.- / Metalloendopeptidases; EC 3.4.24.65 / MMP12 protein, human; EC 3.4.24.65 / Matrix Metalloproteinase 12

[Other-IDs] NLM/ PMC1183473

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Human papillomavirus and anal neoplasia.

Anal cancer is a rare disease in the general population, but the incidence of anal cancer is higher in certain at-risk groups, such as men who have sex with men (MSM), and immunosuppressed individuals, including those with HIV infection.

Among HIV-positive MSM, the incidence of anal cancer may be as high as 10 times greater than current rates of cervical cancer in the general population of women.

Anal cancer is associated with human papillomavirus (HPV) infection and may be preceded by high-grade anal intraepithelial neoplasia (HGAIN).

HGAIN and anal HPV infection are both highly prevalent in groups at risk for anal cancer.

Current issues include determining the effect of antiretroviral therapy on the natural history of HGAIN and the incidence of anal cancer, optimizing diagnostic and therapeutic approaches to HGAIN, and determining the potential for prophylactic HPV vaccines to prevent anal HPV infection and anal cancer in at-risk groups.

[MeSH-major] Anus Neoplasms. Carcinoma in Situ. Papillomavirus Infections

[MeSH-minor] Anus Diseases / epidemiology. Anus Diseases / virology. Female. HIV Infections / complications. Homosexuality, Male. Humans. Male. Papillomaviridae / isolation & purification

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]

[Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]

[Cites] Nat Med. 2007 Jul;13(7):857-61 [17603495.001]

[Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):843-9 [11390533.001]

[Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]

[Cites] J Acquir Immune Defic Syndr. 2008 Jan 1;47(1):56-61 [18156992.001]

[Cites] Dis Colon Rectum. 2003 Nov;46(11):1555-9 [14605579.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]

[Cites] Clin Infect Dis. 2002 Nov 1;35(9):1127-34 [12384848.001]

[Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]

[Cites] N Engl J Med. 2007 May 10;356(19):1928-43 [17494926.001]

[Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]

[Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]

[Cites] Virus Res. 1993 Feb;27(2):133-45 [8384765.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]

[Cites] MMWR Recomm Rep. 2004 Dec 17;53(RR-15):1-112 [15841069.001]

[Cites] Gastroenterol Clin North Am. 2007 Dec;36(4):969-87, ix [17996800.001]

[Cites] Transpl Int. 2004 Aug;17(7):366-9 [15349721.001]

[Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]

[Cites] Curr Opin Infect Dis. 2006 Feb;19(1):14-9 [16374212.001]

[Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]

[Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]

[Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]

[Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]

[Cites] Lancet. 2007 Jun 30;369(9580):2161-2170 [17602732.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Aug 15;27(5):432-42 [11511819.001]

[Cites] Br J Dermatol. 2007 Sep;157(3):523-30 [17573882.001]

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]

[Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]

[Cites] J Infect Dis. 1990 Aug;162(2):358-61 [1973695.001]

[Cites] Cytojournal. 2006 Mar 20;3:4 [16549010.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]

[Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/140-6 [16950001.001]

[Cites] Dis Colon Rectum. 2008 Jun;51(6):829-35; discussion 835-7 [18363070.001]

[Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]

[Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]

[Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]

[Cites] J Am Acad Dermatol. 2004 Jun;50(6):980-1 [15153912.001]

[Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]

[Cites] Dis Colon Rectum. 2008 Jan;51(1):73-81 [18066626.001]

[Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]

[Cites] J Acquir Immune Defic Syndr. 2005 Oct 1;40(2):182-9 [16186736.001]

[Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]

[Cites] Oncology (Williston Park). 2005 Nov;19(12):1634-8; discussion 1638-40, 1645 passim [16396154.001]

[Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]

[Cites] N Engl J Med. 2007 May 10;356(19):1915-27 [17494925.001]

[Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]

[Cites] Int J Cancer. 1996 Nov 27;68(5):559-64 [8938134.001]

[Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]

[Cites] MMWR Recomm Rep. 2007 Mar 23;56(RR-2):1-24 [17380109.001]

(PMID = 18510893.001).

[ISSN] 1548-3568

[Journal-full-title] Current HIV/AIDS reports

[ISO-abbreviation] Curr HIV/AIDS Rep

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] United States

[Number-of-references] 57

   

Advertisement

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Increased epithelial cell proliferation in the ileal pouch mucosa of patients with familial adenomatous polyposis.

To eliminate the risk of colorectal cancer in patients with familial adenomatous polyposis (FAP), reconstructive proctocolectomy is performed.

Although most colonic mucosa is resected during the ileal pouch anal anastomosis, adenomas and carcinomas may develop in the pouch.

This may be caused by altered cell kinetics due to intraluminal changes in the pouch.

Cell proliferation was also assessed by a modified sign test.

However, cell proliferation was significantly higher in the mucosa of the pouch vs afferent ileal loop, both by using the quantitative (68.3% vs 61.6%, p = 0.001) and semiquantitative methods (p < 0.05).

The higher cell proliferation in the pouch as compared to the afferent ileal loop may contribute to the increased risk for adenomas and carcinomas in the pouch of patients with FAP and emphasizes the need for regular endoscopic surveillance.

[MeSH-major] Adenomatous Polyposis Coli / pathology. Cell Division. Colonic Pouches / pathology. Epithelial Cells / pathology

[MeSH-minor] Adenoma / pathology. Adolescent. Adult. Aged. Antibodies, Monoclonal. Apoptosis. Carcinoma / pathology. Colorectal Neoplasms / pathology. Colorectal Neoplasms / prevention & control. Female. Humans. Ileum / pathology. Immunohistochemistry. Intestinal Mucosa / pathology. Male. Middle Aged. Proctocolectomy, Restorative

Genetic Alliance. consumer health - Familial Adenomatous Polyposis (FAP).

Genetic Alliance. consumer health - Familial Polyposis.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Epidemiology. 1996 Sep;7(5):561 [8862998.001]

[Cites] Gastroenterology. 1997 Oct;113(4):1159-62 [9322510.001]

[Cites] Indian J Cancer. 1997 Mar;34(1):16-9 [9491657.001]

[Cites] Dis Colon Rectum. 1998 May;41(5):552-6; discussion 556-7 [9593235.001]

[Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]

[Cites] J Gastrointest Surg. 2005 May-Jun;9(5):695-702 [15862266.001]

[Cites] Gut. 1999 Dec;45(6):822-8 [10562579.001]

[Cites] Gut. 2000 Nov;47(5):732-4 [11034594.001]

[Cites] Dis Colon Rectum. 2001 Nov;44(11):1590-6 [11711729.001]

[Cites] Gut. 2001 Jan;48(1):41-6 [11115821.001]

[Cites] Gut. 2001 Feb;48(2):238-46 [11156647.001]

[Cites] Ann Surg. 2001 Mar;233(3):360-4 [11224623.001]

[Cites] Dis Colon Rectum. 2001 Mar;44(3):347-53 [11289279.001]

[Cites] J Infect Dis. 2001 Jul 15;184(2):227-30 [11424022.001]

[Cites] Mutat Res. 2001 Sep 1;480-481:129-38 [11506806.001]

[Cites] Dis Colon Rectum. 2001 Nov;44(11):1714-5 [11711749.001]

[Cites] Lancet. 2003 Jul 19;362(9379):205-9 [12885482.001]

[Cites] Dis Colon Rectum. 2003 Oct;46(10):1418-23; discussion 1422-3 [14530685.001]

[Cites] Colorectal Dis. 2003 Nov;5(6):592-4 [14617250.001]

[Cites] Gut. 2004 Mar;53(3):381-6 [14960520.001]

[Cites] Dis Colon Rectum. 2004 Apr;47(4):530-4 [14978621.001]

[Cites] Gastroenterology. 1978 Jun;74(6):1325-30 [348556.001]

[Cites] Dis Colon Rectum. 1985 Sep;28(9):664-8 [4053908.001]

[Cites] Gastroenterology. 1987 Mar;92(3):704-8 [3817391.001]

[Cites] Cancer Res. 1988 Jul 15;48(14):4121-6 [3383201.001]

[Cites] Gastroenterology. 1989 Mar;96(3):817-24 [2914643.001]

[Cites] Dis Colon Rectum. 1989 Dec;32(12):1034-8 [2556253.001]

[Cites] J Clin Pathol. 1990 Oct;43(10):824-8 [2172322.001]

[Cites] Cancer Res. 1991 Apr 1;51(7):1917-21 [2004376.001]

[Cites] Gastroenterology. 1992 Apr;102(4 Pt 1):1278-88 [1312975.001]

[Cites] Gastroenterology. 1992 Oct;103(4):1144-53 [1397871.001]

[Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]

[Cites] Br J Surg. 1993 Dec;80(12):1620 [8298944.001]

[Cites] Dis Colon Rectum. 1994 Aug;37(8):824-8 [8055729.001]

[Cites] Gastroenterology. 1995 Sep;109(3):994-8 [7657130.001]

[Cites] Br J Surg. 1996 Apr;83(4):506 [8665242.001]

[Cites] Am J Surg Pathol. 1996 Aug;20(8):995-9 [8712299.001]

[Cites] Gut. 1996 Apr;38(4):549-53 [8707086.001]

(PMID = 17611772.001).

[ISSN] 0945-6317

[Journal-full-title] Virchows Archiv : an international journal of pathology

[ISO-abbreviation] Virchows Arch.

[Language] eng

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Antibodies, Monoclonal

[Other-IDs] NLM/ PMC2039779

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal squamous intraepithelial lesions among HIV positive and HIV negative men who have sex with men in Thailand.

OBJECTIVES: To evaluate the prevalence and risk factors of anal squamous intraepithelial lesions (ASIL), the putative anal cancer precursor, in Asian HIV positive and HIV negative men who have sex with men (MSM).

METHODS: Men who underwent anal Pap smear reported clinical, sociodemographic and behavioural information collected through questionnaire and interview between January 2007 and April 2008.

Overall, 27% had abnormal anal cytology: 13.2% had atypical squamous cells of undetermined significance (ASC-US), 11.5% had low-grade squamous intraepithelial lesion (LSIL) and 2.3% had high-grade squamous intraepithelial lesion (HSIL).

Anal condyloma was detected in 22% of HIV positive and 16.1% (9/56) of HIV negative MSM (p = 0.5).

In HIV positive MSM, anal condyloma (OR 3.42, 95% CI 1.29 to 9.04; p = 0.01) was a significant risk factor for ASIL.

Highly active antiretroviral therapy use and CD4+ T cell count were not associated with ASIL.

Thus, as greater numbers of HIV positive MSM live longer due to increasing access to HAART worldwide, effective strategies to screen and manage anal precancerous lesions are needed.

[MeSH-major] Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Carcinoma, Squamous Cell / epidemiology. HIV Seronegativity / physiology. HIV Seropositivity / epidemiology. Homosexuality, Male / statistics & numerical data

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Semin Oncol. 2000 Aug;27(4):390-401 [10950365.001]

[Cites] Int J STD AIDS. 2008 Aug;19(8):529-32 [18663038.001]

[Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]

[Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]

[Cites] Dis Colon Rectum. 2003 Mar;46(3):367-73 [12626913.001]

[Cites] Am J Epidemiol. 2003 Jun 1;157(11):966-72 [12777359.001]

[Cites] Sex Transm Dis. 2004 Feb;31(2):96-9 [14743072.001]

[Cites] Arch Sex Behav. 2004 Apr;33(2):137-47 [15146146.001]

[Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]

[Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]

[Cites] J Infect Dis. 2004 Nov 1;190(9):1685-91 [15478076.001]

[Cites] N Engl J Med. 1987 Oct 15;317(16):973-7 [2821396.001]

[Cites] AIDS. 1993 Jan;7(1):43-9 [8382927.001]

[Cites] Am J Epidemiol. 1994 Apr 15;139(8):772-80 [8178790.001]

[Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]

[Cites] N Engl J Med. 1997 Nov 6;337(19):1350-8 [9358129.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):320-6 [9525432.001]

[Cites] AIDS. 1998 Mar 26;12(5):495-503 [9543448.001]

[Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]

[Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]

[Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]

[Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]

[Cites] Clin Infect Dis. 2006 Jul 15;43(2):223-33 [16779751.001]

[Cites] MMWR Morb Mortal Wkly Rep. 2006 Aug 11;55(31):844-8 [16902394.001]

[Cites] AIDS. 2007 Jul 11;21(11):1457-65 [17589192.001]

[Cites] Sex Transm Dis. 2008 Feb;35(2):197-202 [18216727.001]

[Cites] Sex Transm Dis. 2008 Aug;35(8):721-4 [18650771.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]

(PMID = 19525263.001).

[ISSN] 1472-3263

[Journal-full-title] Sexually transmitted infections

[ISO-abbreviation] Sex Transm Infect

[Language] eng

[Grant] United States / NIAID NIH HHS / AI / P30 AI050410; United States / NCRR NIH HHS / RR / TL1 RR024978

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ NIHMS527353; NLM/ PMC3875384

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Screening methods for high-grade dysplasia in patients with anal condyloma.

HPV infection can cause anal condylomas and is a risk factor for dysplasia.

High-grade dysplasia may progress to squamous cell carcinoma.

The purpose of this study is to determine whether anal cytology, morphological characteristics, and/or the presence of high-risk oncogenic HPV-types are effective noninvasive methods to detect high-risk anal condylomas.

PATIENTS AND METHODS: From November 2003 to June 2004, all patients with anal condyloma were prospectively evaluated for anal cytology, high-risk oncogenic HPV-types, and tissue biopsies.

RESULTS: Forty-seven patients with anal condyloma were studied; 43 (91.5%) were men, and the mean age was 39 +/- 11 years.

CONCLUSION: Anal cytology alone is not accurate for detecting HRL in patients with anal condylomas.

Combining oncogenic HPV-testing with cytology is more sensitive in detecting HRL in patients with anal condyloma, and therefore, a more effective screening tool.

[MeSH-major] Anal Canal / pathology. Anus Diseases / pathology. Anus Neoplasms / pathology. Condylomata Acuminata / pathology. Papillomaviridae. Papillomavirus Infections / pathology. Tumor Virus Infections / pathology

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Disorders.

MedlinePlus Health Information. consumer health - Genital Warts.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15964301.001).

[ISSN] 0022-4804

[Journal-full-title] The Journal of surgical research

[ISO-abbreviation] J. Surg. Res.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Regression analysis of the initial karyometric data on tumor cells in ductal carcinoma and fibroadenoma of the mammary gland.

OBJECTIVE: To reveal the differences in the parameters of the second order regression curve with a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei between ductal carcinoma and fibroadenoma of the mammary gland.

STUDY DESIGN: Punctate smears taken from patients with ductal carcinoma and fibroadenoma of the mammary gland with coincident histologic and cytologic conclusion were studied and selected.

RESULTS: It has been shown that the cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be well described by a second order regression curve, which is a parabola.

The differences in parabola parameters (coefficients of the parabola equation) characterizing the population of tumor cells in ductal carcinoma and fibroadenoma of the mammary gland were revealed.

CONCLUSION: Parameters of the regression curve to a cluster of experimental points on scattergrams showing the dependence of the perimeter on the area of tumor cell nuclei can be used as an additional diagnostic criterion for breast cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 20701078.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Chemoradiotherapy combined with intracavitary hyperthermia for anal cancer: feasibility and long-term results from a phase II randomized trial.

PURPOSE: The purpose of this study was to investigate in a randomized way the clinical benefit of addition of intracavitary hyperthermia (ICHT) to a conventional chemoradiotherapy schedule in patients with T2-T3N0M0 anal cancer.

A microwave applicator operating at 433 MHz inserted into the anal-rectal cavity was used for ICHT.

CONCLUSION: The addition of ICHT to the chemoradiotherapy schedule of anal cancer seems to offer a new effective and safe therapeutic modality.

[MeSH-major] Anus Neoplasms / therapy. Diathermy

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

Hazardous Substances Data Bank. MITOMYCIN C .

Hazardous Substances Data Bank. FLUOROURACIL .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15685041.001).

[ISSN] 1537-453X

[Journal-full-title] American journal of clinical oncology

[ISO-abbreviation] Am. J. Clin. Oncol.

[Language] eng

[Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial

[Publication-country] United States

[Chemical-registry-number] 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Effect of poly (ADP-ribose) polymerase-1 inhibition on the proliferation of murine colon carcinoma CT26 cells.

MTT assays and flow cytometry were used to determine the proliferation and cell cycle distribution, respectively, of the cells.

These results suggest that PARP inhibition reduced the proliferation of CT26 cells in vitro and influences the cell cycle.

[MeSH-major] Cell Proliferation / drug effects. Colonic Neoplasms / enzymology. Enzyme Inhibitors / pharmacology. NF-kappa B / drug effects. Poly(ADP-ribose) Polymerases / metabolism

[MeSH-minor] Animals. Blotting, Western. Cell Cycle. Cell Line, Tumor. Cell Separation. Electrophoretic Mobility Shift Assay. Flow Cytometry. Isoquinolines / pharmacology. Mice. Poly (ADP-Ribose) Polymerase-1

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Zhonghua Fu Chan Ke Za Zhi. 2004 Aug;39(8):533-7 [15363352.001]

[Cites] Cancer Res. 2004 Sep 1;64(17):6344-8 [15342424.001]

[Cites] Am J Physiol Cell Physiol. 2005 Jul;289(1):C82-8 [15743888.001]

[Cites] Med Sci Monit. 2002 Nov;8(11):BR444-53 [12444369.001]

[Cites] Cancer Res. 2004 Dec 15;64(24):8960-7 [15604259.001]

[Cites] Eur J Cancer. 2006 Sep;42(14 ):2374-81 [16809031.001]

[Cites] Naunyn Schmiedebergs Arch Pharmacol. 2004 Dec;370(6):464-73 [15599708.001]

[Cites] Biochem Biophys Res Commun. 2006 Dec 1;350(4):1056-62 [17046715.001]

[Cites] Ai Zheng. 2007 Jun;26(6):566-71 [17562258.001]

[Cites] Curr Med Chem. 2005;12 (20):2373-92 [16181138.001]

[Cites] Cell. 2004 Aug 6;118(3):285-96 [15294155.001]

[Cites] Clin Cancer Res. 2007 May 15;13(10):3033-42 [17505006.001]

[Cites] Anal Biochem. 1996 May 1;236(2):302-8 [8660509.001]

[Cites] Eksp Onkol. 2004 Mar;26(1):40-7 [15112579.001]

[Cites] Zhonghua Nei Ke Za Zhi. 2002 Sep;41(9):605-9 [12421493.001]

[Cites] J Pharmacol Exp Ther. 2005 Feb;312(2):449-57 [15452194.001]

[Cites] Br J Pharmacol. 2000 Jun;130(4):843-50 [10864891.001]

[Cites] J Biol Chem. 2004 Oct 8;279(41):42774-86 [15302869.001]

[Cites] Biochem Pharmacol. 2002 Jan 15;63(2):293-304 [11841805.001]

(PMID = 18989759.001).

[ISSN] 1532-2807

[Journal-full-title] Pathology oncology research : POR

[ISO-abbreviation] Pathol. Oncol. Res.

[Language] eng

[Publication-type] Journal Article

[Publication-country] Netherlands

[Chemical-registry-number] 0 / 5-aminoisoquinolinone; 0 / Enzyme Inhibitors; 0 / Isoquinolines; 0 / NF-kappa B; EC 2.4.2.30 / Parp1 protein, mouse; EC 2.4.2.30 / Poly (ADP-Ribose) Polymerase-1; EC 2.4.2.30 / Poly(ADP-ribose) Polymerases

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Magnetic resonance imaging of anal cancer.

AIM: The purpose of this study was to evaluate the magnetic resonance imaging (MRI) appearances of primary and recurrent anal carcinoma, and to demonstrate the commonest patterns of local and distant disease spread.

METHODS: A retrospective review was performed of 27 cases of biopsy-proven anal carcinoma, where MRI was used for primary staging (9 patients) or suspected recurrence (18 patients).

The size, extent and signal characteristics of the anal tumour were documented.

Lymph node metastases were of similar signal intensity to the anal cancer.

[MeSH-major] Anus Neoplasms / pathology. Carcinoma, Squamous Cell / pathology. Lymphatic Metastasis / pathology. Magnetic Resonance Imaging / methods. Neoplasm Recurrence, Local / pathology

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - MRI Scans.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 16179172.001).

[ISSN] 0009-9260

[Journal-full-title] Clinical radiology

[ISO-abbreviation] Clin Radiol

[Language] eng

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] England

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Anal dysplasia screening: an evidence-based analysis.

OBJECTIVE: This review considered the role of the anal Pap test as a screening test for anal dysplasia in patients at high risk of anal SCC.

CLINICAL NEED: TARGET POPULATION AND CONDITION Anal cancer, like cervical cancer, is a member of a broader group of anogenital cancers known to be associated with sexually transmitted viral HPV infection.

Sexual practices involving receptive anal intercourse lead to significantly elevated risk for anal dysplasia and cancer, particularly in those with immune dysfunctions.

Anal cancer is rare.

It is the least common of the lower gastrointestinal cancers, representing about 4% of them, in contrast to colorectal cancers, which remain the third most commonly diagnosed malignancy.

Certain segments of the population, however, such as HIV-positive men and women, other chronic immune-suppressed patients (e.g., after a transplant), injection drug users, and women with genital dysplasia /cancer, have a high susceptibility to anal cancer.

Those with the highest identified risk for anal cancer are HIV-positive homosexual and bisexual men, at a rate of 70 per 100,000 men.

The risk for anal cancer is reported to be increasing dramatically in HIV-positive males and females, particularly since the introduction of highly active antiretroviral therapy in the mid-1990s.

HEALTH TECHNOLOGY DESCRIPTION: Anal Pap test screening involves the blind insertion of a swab into the anal canal and fixing cells either on a slide or in fluid for cytological examination.

Anal cytology classified by the standardized Bethesda System is the same classification used for cervical cytology.

It has 4 categories: normal, atypical squamous cells of uncertain significance, or squamous intraepithelial lesions which are further classified into low- or high-grade lesions.

Unlike cervical cancer, there are no universally accepted guidelines or standards of care for anal dysplasia.

The New York State Department of Health AIDS Institute has recently recommended (March 2007) annual anal pap testing in high-risk groups.

In Ontario, reimbursement exists only for Pap tests for cervical cancer screening.

That is, there is no reimbursement for anal Pap testing in men or women, and HPV screening tests for cervical or anal cancer are also not reimbursed.

Assessments of current practices were obtained through consultations with various agencies and individuals including the Ministry of Health and Long-Term Care AIDS Bureau; Public Health Infectious Diseases Branch, Ministry of Health and Long-Term Care; Cancer Care Ontario; HIV/AIDS researchers; pathology experts; and HIV/AIDS clinical program directors.

FINDINGS: No direct evidence was found for the existence of controlled studies evaluating the effectiveness of anal Pap test screening programs for impact on anal cancer morbidity or mortality.

In addition, no studies were found on the use of HPV DNA testing in the screening or diagnostic setting for anal dysplasia.

The reported prevalence of HPV infection in high-risk groups, particularly HIV-positive males, however, was sufficiently high to preclude any utility of HPV testing as an adjunct to anal Pap testing.

Nine reports involving studies in the United States, United Kingdom, and Canada were identified that evaluated the performance characteristics of anal Pap test screening for anal dysplasia.

Estimates of anal Pap test sensitivity and specificity were highly variable, and depended on the varying prevalence of cytology abnormality and differential thresholds for abnormality for both cytology and histopathology.

CONCLUSIONS: No direct evidence exists to support the effectiveness of an anal Pap test screening program to reduce anal cancer mortality or morbidity.

There are, however, strong parallels with cervical pap testing for cervical cancer.

Sexually transmitted HPV viral infection is currently the acknowledged common causative agent for both anal and cervical cancer.

Anal cancer rates in high-risk populations are approaching those of cervical cancer before the implementation of Pap testing.

The anal Pap test, although it has been mainly evaluated only in HIV-positive males, has similar operating characteristics of sensitivity and specificity as the cervical Pap test.

In general, the treatment options for precancer dysplasia in the cervix and the anus are similar, but treatment involving a definitive surgical resection in the anus is more limited because of the higher risk of complications.

A range of ablative therapies has been applied for anal dysplasia, but evidence on treatment effectiveness, tolerability and durability, particularly in the HIV-positive patient, is limited.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] N Engl J Med. 1992 Oct 29;327(18):1272-8 [1328880.001]

[Cites] Lancet. 1991 Sep 14;338(8768):657-9 [1679474.001]

[Cites] Cancer Res. 1991 Feb 1;51(3):1014-9 [1846314.001]

[Cites] JAMA. 1989 Aug 18;262(7):931-4 [2754794.001]

[Cites] Am J Epidemiol. 1995 Apr 1;141(7):680-9 [7702044.001]

[Cites] J Clin Pathol. 1994 Nov;47(11):1032-4 [7829679.001]

[Cites] Br J Surg. 1994 Aug;81(8):1238-40 [7953374.001]

[Cites] Br J Surg. 1994 Mar;81(3):365-7 [8173899.001]

[Cites] Genitourin Med. 1994 Feb;70(1):22-5 [8300094.001]

[Cites] BMJ. 1993 Feb 13;306(6875):419-22 [8461721.001]

[Cites] AIDS. 1995 Nov;9(11):1255-62 [8561979.001]

[Cites] Gynecol Oncol. 1997 Feb;64(2):213-23 [9038266.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Apr 15;14(5):415-22 [9170415.001]

[Cites] J Acquir Immune Defic Syndr Hum Retrovirol. 1998 Apr 1;17(4):314-9 [9525431.001]

[Cites] Obstet Gynecol. 1998 Jun;91(6):973-6 [9611007.001]

[Cites] JAMA. 1999 May 19;281(19):1822-9 [10340370.001]

[Cites] Obstet Gynecol Surv. 1999 Jul;54(7):469-76 [10394585.001]

[Cites] J Clin Microbiol. 1999 Aug;37(8):2508-17 [10405393.001]

[Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]

[Cites] J Clin Microbiol. 2000 Jan;38(1):357-61 [10618116.001]

[Cites] Dis Colon Rectum. 2000 Mar;43(3):346-52 [10733116.001]

[Cites] Arch Pathol Lab Med. 2000 May;124(5):672-81 [10782146.001]

[Cites] Ann Intern Med. 2000 May 16;132(10):810-9 [10819705.001]

[Cites] Am J Med. 2000 Jun 1;108(8):634-41 [10856411.001]

[Cites] Epidemiology. 2000 Jul;11(4):457-61 [10874555.001]

[Cites] Drug Saf. 2000 Aug;23(2):101-13 [10945373.001]

[Cites] J Natl Cancer Inst. 2000 Sep 20;92(18):1500-10 [10995805.001]

[Cites] J Infect Dis. 2001 Feb 1;183(3):383-91 [11133369.001]

[Cites] Dis Colon Rectum. 2001 Feb;44(2):236-42 [11227941.001]

[Cites] JAMA. 2001 Mar 21;285(11):1500-5 [11255427.001]

[Cites] Dermatol Surg. 2001 Jun;27(6):561-4 [11442593.001]

[Cites] Vaccine. 2006 Aug 31;24 Suppl 3:S3/42-51 [16950017.001]

[Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]

[Cites] Gynecol Oncol. 2001 Sep;82(3):516-22 [11520149.001]

[Cites] Sex Transm Infect. 2001 Oct;77(5):327-31 [11588276.001]

[Cites] J Clin Pathol. 2002 Apr;55(4):244-65 [11919208.001]

[Cites] JAMA. 2002 Apr 24;287(16):2114-9 [11966386.001]

[Cites] JAMA. 2002 Apr 24;287(16):2120-9 [11966387.001]

[Cites] J Infect Dis. 2002 May 1;185(9):1229-37 [12001039.001]

[Cites] Clin Cancer Res. 2002 May;8(5):1028-37 [12006515.001]

[Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]

[Cites] Dis Colon Rectum. 2002 Apr;45(4):502-7 [12006932.001]

[Cites] Int J Colorectal Dis. 2002 Jul;17(4):203-15 [12073068.001]

[Cites] Prev Med. 2003 May;36(5):555-60 [12689800.001]

[Cites] Colorectal Dis. 2003 Jul;5(4):353-7 [12814415.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):915-20 [15220697.001]

[Cites] Cancer. 2004 Jul 15;101(2):281-8 [15241824.001]

[Cites] Clin Infect Dis. 2004 Sep 1;39(5):609-29 [15356773.001]

[Cites] J Infect Dis. 2004 Dec 15;190(12):2070-6 [15551204.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1563-5 [15577408.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1610-5 [15577418.001]

[Cites] Cancer. 2005 Apr 1;103(7):1447-56 [15726546.001]

[Cites] Br J Surg. 2005 Mar;92(3):277-90 [15736144.001]

[Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S43-51 [15753011.001]

[Cites] Sex Transm Infect. 2005 Apr;81(2):142-6 [15800092.001]

[Cites] Sex Transm Dis. 2005 May;32(5):314-20 [15849533.001]

[Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]

[Cites] J Natl Cancer Inst. 2005 Jun 15;97(12):896-905 [15956651.001]

[Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]

[Cites] AIDS. 2005 Sep 2;19(13):1407-14 [16103772.001]

[Cites] Int J Colorectal Dis. 2007 Jan;22(1):1-5 [16133005.001]

[Cites] Surg Oncol. 2005 Nov;14(3):121-32 [16165347.001]

[Cites] J Acquir Immune Defic Syndr. 2005 Dec 1;40(4):451-5 [16280701.001]

[Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]

[Cites] Lancet Infect Dis. 2006 Jan;6(1):21-31 [16377531.001]

[Cites] Cytojournal. 2006;3:4 [16549010.001]

[Cites] Br J Surg. 2006 May;93(5):531-8 [16607677.001]

[Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]

[Cites] Gynecol Oncol. 2003 Jul;90(1):131-6 [12821353.001]

[Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):638-42 [12869403.001]

[Cites] Dis Colon Rectum. 2003 Aug;46(8):1103-8; discussion 1108-9 [12907906.001]

[Cites] Cancer. 1953 Sep;6(5):963-8 [13094644.001]

[Cites] Br J Cancer. 2003 Oct 6;89(7):1221-7 [14520450.001]

[Cites] Dis Colon Rectum. 2003 Oct;46(10):1332-6; discussion 1336-8 [14530670.001]

[Cites] Cancer. 2004 Feb 25;102(1):19-26 [14968414.001]

[Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):277-93 [15137957.001]

[Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]

[Cites] J Am Acad Dermatol. 2004 Jun;50(6):980-1 [15153912.001]

[Cites] Clin Infect Dis. 2004 May 15;38(10):1490-2 [15156490.001]

[Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]

(PMID = 23074504.001).

[ISSN] 1915-7398

[Journal-full-title] Ontario health technology assessment series

[ISO-abbreviation] Ont Health Technol Assess Ser

[Language] eng

[Publication-type] Journal Article

[Publication-country] Canada

[Other-IDs] NLM/ PMC3377578

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays.

The effective targeting of malignant cell surface antigens is essential in cancer therapy.

Resistance to treatment and rapid invasion of cancer cells are the main causes of cancer mortality.

To assess the treatment response, we cultured a 3-D MCF-7 cell line overexpressing HER-2 and CD44 receptors.

The high density 3-D cell aggregation in the hollow fiber bioreactor (HFB) used for the cell culture was monitored with the use of proton magnetic resonance imaging ((1)H MRI).

The data also demonstrate that HA could be used to enhance treatment efficacy of trastuzumab and anti-HER-2 (clone CB11) in breast cancer cell cultures.

[MeSH-minor] Antibodies, Monoclonal / administration & dosage. Antibodies, Monoclonal, Humanized. Antigens, CD44 / immunology. Cell Line, Tumor. Cell Survival / drug effects. Chromatography, High Pressure Liquid / methods. DNA / administration & dosage. Drug Resistance, Neoplasm. Drug Synergism. Female. Humans. Hyaluronic Acid / administration & dosage. Lipids / administration & dosage. Magnetic Resonance Imaging / methods. Plasmids / administration & dosage. Receptor, ErbB-2 / immunology. Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / methods. Trastuzumab

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Trastuzumab .

Hazardous Substances Data Bank. HYALURONIC ACID .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19709839.001).

[ISSN] 1873-264X

[Journal-full-title] Journal of pharmaceutical and biomedical analysis

[ISO-abbreviation] J Pharm Biomed Anal

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD44; 0 / Lipids; 0 / Lipofectamine; 9004-61-9 / Hyaluronic Acid; 9007-49-2 / DNA; EC 2.7.10.1 / Receptor, ErbB-2; P188ANX8CK / Trastuzumab

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Unusual iris metastasis from anal cancer: a case report.

We report a case of anal cancer with iris metastasis and summarize the iris metastasis literature.

A 69 years old woman with a history of anal cancer presented with a visual field loss.

Because of worse prognosis of metastatic cancer and any ocular complications, the patient was treated by radiotherapy which allowed a clinical improvement.

A review of medical records was performed to assess the clinical presentation, diagnosis and treatment.

Anal carcinoma can metastasize to the iris.

[MeSH-major] Anus Neoplasms / pathology. Iris Neoplasms / secondary

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18294934.001).

[ISSN] 1878-3562

[Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver

[ISO-abbreviation] Dig Liver Dis

[Language] eng

[Publication-type] Case Reports; Journal Article

[Publication-country] Netherlands

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia.

To examine the role of this zinc finger protein in skin, we expressed the wild-type human allele from inducible and constitutive promoters.

KLF4 caused a transitory apoptotic response and the skin progressed through phases of hyperplasia and dysplasia.

By 6 weeks, lesions exhibited nuclear KLF4 and other morphologic and molecular similarities to squamous cell carcinoma in situ. p53 determined the patch size sufficient to establish lesions, as induction in a mosaic pattern produced skin lesions only when p53 was deficient.

The results suggest that KLF4 can function in the nucleus to induce squamous epithelial dysplasia, and indicate roles for p53 and epithelial-mesenchymal signaling in these early neoplastic lesions.

COS Scholar Universe. author profiles.

Addgene Non-profit plasmid repository. clones/clone libraries - Get Article's Plasmids - Addgene (subscription/membership/fee required).

Hazardous Substances Data Bank. DOXORUBICIN .

Jackson Laboratory JAX®Mice Database. culture/stock collections - FVB.Cg-Tg(tetO-KLF4)32831Rup/Mmjax (subscription/membership/fee required).

KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).

Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

SciCrunch. Marmoset Gene list: Data: Gene Annotation .

The Lens. Cited by Patents in .

eagle-i research resources. PMID 15674344 (Special Collections) .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2001 Jul 20;276(29):26737-40 [11389134.001]

[Cites] Cancer Surv. 1998;32:69-113 [10489624.001]

[Cites] Curr Opin Cell Biol. 2001 Dec;13(6):778-84 [11698196.001]

[Cites] Nat Genet. 2001 Dec;29(4):418-25 [11694875.001]

[Cites] N Engl J Med. 2001 Dec 27;345(26):1890-900 [11756581.001]

[Cites] Development. 2002 Jun;129(11):2619-28 [12015290.001]

[Cites] J Invest Dermatol. 2002 Jun;118(6):998-1002 [12060394.001]

[Cites] Trends Cell Biol. 2001 Nov;11(11):S2-9 [11684435.001]

[Cites] Nucleic Acids Res. 1999 Dec 1;27(23):4562-9 [10556311.001]

[Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]

[Cites] J Biol Chem. 2000 Jun 16;275(24):18391-8 [10749849.001]

[Cites] Nucleic Acids Res. 2000 Aug 1;28(15):2969-76 [10908361.001]

[Cites] J Biol Chem. 2000 Dec 1;275(48):37798-806 [10954723.001]

[Cites] Cancer Res. 2000 Nov 15;60(22):6488-95 [11103818.001]

[Cites] Nature. 2001 Apr 26;410(6832):1111-6 [11323676.001]

[Cites] Cancer Res. 2002 Oct 15;62(20):5867-73 [12384550.001]

[Cites] Cell. 2002 Oct 18;111(2):241-50 [12408868.001]

[Cites] J Biol Chem. 2003 Mar 28;278(13):11661-9 [12538588.001]

[Cites] Cancer Cell. 2003 Mar;3(3):203-5 [12676578.001]

[Cites] Development. 2003 Jun;130(12):2767-77 [12736219.001]

[Cites] Oncogene. 2003 May 29;22(22):3424-30 [12776194.001]

[Cites] Curr Opin Cell Biol. 2003 Dec;15(6):763-70 [14644203.001]

[Cites] Am J Physiol Gastrointest Liver Physiol. 2004 Jan;286(1):G23-30 [12919939.001]

[Cites] Cancer Cell. 2003 Nov;4(5):383-91 [14667505.001]

[Cites] Cancer Cell. 2003 Dec;4(6):425-9 [14706334.001]

[Cites] Oncogene. 2004 Jan 15;23(2):395-402 [14724568.001]

[Cites] Cell. 2004 Jan 23;116(2):235-46 [14744434.001]

[Cites] Cancer Cell. 2004 Apr;5(4):311-6 [15093538.001]

[Cites] Clin Cancer Res. 2004 Apr 15;10(8):2709-19 [15102675.001]

[Cites] Clin Cancer Res. 2004 Jun 1;10(11):3815-24 [15173090.001]

[Cites] Anal Biochem. 1987 Apr;162(1):156-9 [2440339.001]

[Cites] J Cell Sci. 1987 Oct;88 ( Pt 3):305-12 [3129440.001]

[Cites] Cancer Res. 1989 Jul 15;49(14):3713-21 [2660980.001]

[Cites] Cell Differ Dev. 1990 Apr;30(1):27-34 [2350734.001]

[Cites] Cell. 1990 Jun 15;61(6):1147-55 [2161707.001]

[Cites] Nature. 1991 Jul 25;352(6333):345-7 [1852210.001]

[Cites] Nature. 1992 Mar 19;356(6366):215-21 [1552940.001]

[Cites] Cell. 1993 Sep 10;74(5):813-22 [8374952.001]

[Cites] Cancer Res. 1993 Oct 1;53(19):4477-80 [8402617.001]

[Cites] J Virol. 1994 Jul;68(7):4358-68 [7515971.001]

[Cites] Nature. 1994 Dec 22-29;372(6508):773-6 [7997263.001]

[Cites] Nucleic Acids Res. 1995 May 25;23(10):1686-90 [7784172.001]

[Cites] Cancer Metastasis Rev. 1995 Jun;14(2):113-24 [7554029.001]

[Cites] Methods Enzymol. 1995;254:3-20 [8531694.001]

[Cites] Science. 1996 Jun 14;272(5268):1621-5 [8658135.001]

[Cites] Science. 1996 Jun 14;272(5268):1668-71 [8658145.001]

[Cites] J Cell Biochem. 1995 Dec;59(4):463-72 [8749716.001]

[Cites] J Biol Chem. 1996 Aug 16;271(33):20009-17 [8702718.001]

[Cites] J Biol Chem. 1996 Dec 6;271(49):31384-90 [8940147.001]

[Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):14025-9 [8943054.001]

[Cites] Am J Pathol. 1996 Dec;149(6):1899-917 [8952526.001]

[Cites] Nature. 1997 Apr 24;386(6627):761, 763 [9126728.001]

[Cites] Eur Arch Otorhinolaryngol. 1997;254(8):376-83 [9332893.001]

[Cites] FEBS Lett. 1997 Dec 15;419(2-3):239-43 [9428642.001]

[Cites] J Biol Chem. 1998 Apr 24;273(17):10747-54 [9553140.001]

[Cites] J Biol Chem. 1998 Jul 10;273(28):17917-25 [9651398.001]

[Cites] J Cell Biol. 1998 Oct 19;143(2):469-86 [9786956.001]

[Cites] J Cell Biochem Suppl. 1998;30-31:111-22 [9893262.001]

[Cites] Oncogene. 1999 Jun 17;18(24):3593-607 [10380881.001]

[Cites] Cell Growth Differ. 1999 Jun;10(6):423-34 [10392904.001]

[Cites] Nat Genet. 1999 Aug;22(4):356-60 [10431239.001]

[Cites] Nature. 2001 May 17;411(6835):349-54 [11357142.001]

(PMID = 15674344.001).

[ISSN] 0950-9232

[Journal-full-title] Oncogene

[ISO-abbreviation] Oncogene

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P30CA13148; United States / NCI NIH HHS / CA / P50 CA089019; United States / NCI NIH HHS / CA / P30 CA013148; United States / NCI NIH HHS / CA / R01 CA094030; United States / NCI NIH HHS / CA / R29 CA065686; United States / NCI NIH HHS / CA / CA89019; United States / NCI NIH HHS / CA / R01 CA065686; United States / NCI NIH HHS / CA / CA65686; United States / NCI NIH HHS / CA / CA094030

[Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.

[Publication-country] England

[Chemical-registry-number] 0 / DNA Primers; 0 / DNA-Binding Proteins; 0 / GKLF protein; 0 / Kruppel-Like Transcription Factors; 0 / Transcription Factors; 80168379AG / Doxorubicin

[Other-IDs] NLM/ NIHMS7908; NLM/ PMC1361530

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Full-length cytokeratin-19 is released by human tumor cells: a potential role in metastatic progression of breast cancer.

INTRODUCTION: We evaluated whether CK19, one of the main cytoskeleton proteins of epithelial cells, is released as full-length protein from viable tumor cells and whether this property is relevant for metastatic progression in breast cancer patients.

METHODS: EPISPOT (EPithelial ImmunoSPOT) assays were performed to analyze the release of full-length CK19 by carcinoma cells of various origins, and the sequence of CK19 was analyzed with mass spectrometry.

CK19-EPISPOT was used to detect disseminated tumor cells in bone marrow (BM) of 45 breast cancer patients who were then followed up over a median of 6 years.

RESULTS: CK19 was expressed and released by colorectal (HT-29, HCT116, Caco-2) and breast (MCF-7, SKBR3, and MDA-MB-231) cancer cell lines.

Functional experiments indicated that CK19 release was an active process and not simply the consequence of cell death.

CK19-releasing cells (RCs) were detectable in BM of 44% to 70% of breast cancer patients.

CONCLUSIONS: Full-length CK19 is released by viable epithelial tumor cells, and CK19-RCs might constitute a biologically active subset of breast cancer cells with high metastatic properties.

[MeSH-minor] Adult. Aged. Bone Marrow Cells / metabolism. Cell Line, Tumor. Disease Progression. Epithelial Cells / metabolism. Epitopes. Female. Humans. Middle Aged. Multivariate Analysis. Neoplasm Metastasis

Genetic Alliance. consumer health - Breast Cancer.

Genetic Alliance. consumer health - Metastatic cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Curr Opin Cell Biol. 2002 Feb;14(1):110-22 [11792552.001]

[Cites] Breast Cancer Res Treat. 2009 Sep;117(1):219-21 [18853248.001]

[Cites] Histopathology. 2002 May;40(5):403-39 [12010363.001]

[Cites] J Cell Biochem. 2002;85(4):670-7 [11968007.001]

[Cites] Anal Chem. 2003 Feb 1;75(3):663-70 [12585499.001]

[Cites] Cell Prolif. 2003 Oct;36 Suppl 1:33-44 [14521514.001]

[Cites] Mol Cell Proteomics. 2004 Jan;3(1):73-81 [14593079.001]

[Cites] Trends Endocrinol Metab. 2004 Jul;15(5):193-7 [15223047.001]

[Cites] Cancer Detect Prev. 1983;6(1-2):41-50 [6883392.001]

[Cites] J Immunol Methods. 1983 Dec 16;65(1-2):109-21 [6361139.001]

[Cites] J Submicrosc Cytol. 1985 Jul;17(3):357-61 [2410624.001]

[Cites] Can J Biochem Cell Biol. 1985 Jun;63(6):680-90 [2412674.001]

[Cites] N Engl J Med. 2000 Feb 24;342(8):525-33 [10684910.001]

[Cites] Anticancer Res. 2000 May-Jun;20(3B):2241-3 [10928185.001]

[Cites] Clin Cancer Res. 2000 Aug;6(8):3117-22 [10955792.001]

[Cites] Int J Cancer. 2001 Feb 15;91(4):468-73 [11251967.001]

[Cites] Cancer Res. 2001 Mar 1;61(5):1890-5 [11280743.001]

[Cites] Int J Oncol. 2002 Jan;20(1):31-7 [11743639.001]

[Cites] Eur J Cell Biol. 1988 Dec;47(2):300-19 [2468493.001]

[Cites] Cancer Res. 1993 Jan 1;53(1):61-6 [7677981.001]

[Cites] J Virol. 1994 Aug;68(8):4857-61 [8035484.001]

[Cites] Annu Rev Biochem. 1994;63:345-82 [7979242.001]

[Cites] Eur J Biochem. 1995 Jul 15;231(2):475-85 [7543411.001]

[Cites] Nat Med. 1995 Oct;1(10):1035-9 [7489359.001]

[Cites] J Biol Chem. 1997 Dec 26;272(52):33197-203 [9407108.001]

[Cites] J Pathol. 1999 Apr;187(5):567-72 [10398123.001]

[Cites] J Immunol Methods. 2005 Apr;299(1-2):177-88 [15914200.001]

[Cites] Clin Chem. 2005 Aug;51(8):1538-41 [16040853.001]

[Cites] N Engl J Med. 2005 Aug 25;353(8):793-802 [16120859.001]

[Cites] Nature. 2006 May 18;441(7091):362-5 [16710422.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Nov 14;103(46):17361-5 [17079488.001]

[Cites] Clin Chem. 2007 Mar;53(3):537-9 [17327507.001]

[Cites] Nat Rev Cancer. 2008 May;8(5):329-40 [18404148.001]

[Cites] Clin Cancer Res. 2008 Jun 15;14(12):3646-50 [18559576.001]

[Cites] Methods Mol Biol. 2008;484:97-109 [18592175.001]

[Cites] J Proteome Res. 2008 Jul;7(7):3060-3 [18494517.001]

[Cites] Clin Cancer Res. 2008 Aug 15;14(16):5013-21 [18698019.001]

[Cites] J Natl Cancer Inst. 2009 Jan 7;101(1):61-6 [19116383.001]

[Cites] Mol Oncol. 2007 Dec;1(3):267-8 [19383302.001]

[Cites] Nat Rev Clin Oncol. 2009 Jun;6(6):339-51 [19399023.001]

[Cites] Genes Dev. 2002 Mar 15;16(6):693-706 [11914275.001]

(PMID = 19549321.001).

[ISSN] 1465-542X

[Journal-full-title] Breast cancer research : BCR

[ISO-abbreviation] Breast Cancer Res.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Epitopes; 0 / Keratin-19

[Other-IDs] NLM/ PMC2716508

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Prognosis and morphometrical features of non-bronchioloalveolar cell adenocarcinoma: an assessment of the non-alveolar replacing area and high grade atypical area.

AIM: It has become obvious that the prognosis of bronchioloalveolar cell carcinoma (BAC) in small peripheral adenocarcinoma of the lung is good, but most cases actually treated as pulmonary adenocarcinoma in hospitals tend to be non-bronchioloalveolar cell carcinoma (non-BAC).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Ann Thorac Surg. 1999 Dec;68(6):2069-73 [10616979.001]

[Cites] Ann Thorac Surg. 2000 Mar;69(3):893-7 [10750779.001]

[Cites] Lung Cancer. 2000 Sep;29(3):179-88 [10996420.001]

[Cites] Cancer Res. 2001 Nov 1;61(21):7950-4 [11691817.001]

[Cites] Am J Surg Pathol. 2003 Jul;27(7):937-51 [12826886.001]

[Cites] Am J Clin Pathol. 1999 May;111(5):610-22 [10230351.001]

[Cites] Anal Quant Cytol. 1982 Sep;4(3):225-32 [7149488.001]

[Cites] Mod Pathol. 1990 May;3(3):314-20 [2362938.001]

[Cites] Am J Surg Pathol. 1990 Oct;14(10):904-12 [2403196.001]

[Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]

[Cites] Am J Surg Pathol. 1996 May;20(5):553-62 [8619420.001]

[Cites] Am J Surg Pathol. 2004 Feb;28(2):198-206 [15043309.001]

(PMID = 16505277.001).

[ISSN] 0021-9746

[Journal-full-title] Journal of clinical pathology

[ISO-abbreviation] J. Clin. Pathol.

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] England

[Other-IDs] NLM/ PMC1860342

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Dissecting genetic requirements of human breast tumorigenesis in a tissue transgenic model of human breast cancer in mice.

Breast cancer development is a complex pathobiological process involving sequential genetic alterations in normal epithelial cells that results in uncontrolled growth in a permissive microenvironment.

Accordingly, physiologically relevant models of human breast cancer that recapitulate these events are needed to study cancer biology and evaluate therapeutic agents.

Here, we report the generation and utilization of the human breast cancer in mouse (HIM) model, which is composed of genetically engineered primary human breast epithelial organoids and activated human breast stromal cells.

Tumor development in the HIM model proceeds through defined histological stages of hyperplasia, DCIS to invasive carcinoma.

The HIM model is an experimentally tractable human in vivo system that holds great potential for advancing our basic understanding of cancer biology and for the discovery and testing of targeted therapies.

[MeSH-major] Breast Neoplasms / genetics. Breast Neoplasms / pathology. Cell Transformation, Neoplastic / genetics. Cell Transformation, Neoplastic / pathology

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Int J Cancer. 2002 Mar 20;98(3):415-8 [11920593.001]

[Cites] Ann Oncol. 2001;12 Suppl 1:S15-9 [11521715.001]

[Cites] Endocrinology. 2002 Dec;143(12):4886-96 [12446616.001]

[Cites] Cancer Cell. 2003 May;3(5):483-95 [12781366.001]

[Cites] Proc Natl Acad Sci U S A. 2004 Apr 6;101(14):4966-71 [15051869.001]

[Cites] Cancer Chemother Biol Response Modif. 2003;21:223-33 [15338747.001]

[Cites] Cancer Res. 1992 Oct 1;52(19):5291-8 [1394133.001]

[Cites] Anal Quant Cytol Histol. 1992 Dec;14(6):433-45 [1363346.001]

[Cites] J Biol Chem. 1996 Mar 29;271(13):7673-8 [8631805.001]

[Cites] Pathol Int. 1998 Jul;48(7):518-25 [9701014.001]

[Cites] Biochem Biophys Res Commun. 1998 Oct 20;251(2):609-12 [9792821.001]

[Cites] Genes Dev. 1999 Sep 15;13(18):2388-99 [10500096.001]

[Cites] Cancer Res. 2004 Nov 1;64(21):7678-81 [15520168.001]

[Cites] J Clin Oncol. 2005 Apr 10;23(11):2460-8 [15710948.001]

[Cites] Nat Rev Drug Discov. 2006 Sep;5(9):741-54 [16915232.001]

[Cites] Hum Pathol. 2008 Feb;39(2):167-74 [18045647.001]

[Cites] Cancer Genet Cytogenet. 1999 Oct 15;114(2):154-5 [10549274.001]

[Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]

[Cites] Genes Dev. 2001 Jan 1;15(1):50-65 [11156605.001]

[Cites] N Engl J Med. 2001 Mar 15;344(11):783-92 [11248153.001]

[Cites] Am J Nurs. 2001 Apr;101(4):11 [11301675.001]

[Cites] Science. 2002 Apr 19;296(5567):550-3 [11910072.001]

(PMID = 19369208.001).

[ISSN] 1091-6490

[Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America

[ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Tumor Suppressor Protein p53; 136601-57-5 / Cyclin D1; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.10.1 / Receptor, ErbB-2; EC 2.7.7.49 / Telomerase; EC 3.6.5.2 / ras Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Beryllium sulfate induces p21 CDKN1A expression and a senescence-like cell cycle arrest in susceptible cancer cell types.

It is not known whether Be(2+) can affect the proliferation of cancer cells, which are generally unsusceptible to senescence.

A172 glioblastoma and RKO colon carcinoma cell lines each have wildtype p53, so these cell types have the potential to be responsive to agents that activate p53.

In A172 cells, BeSO(4) produced a G(0)/G(1)-phase cell cycle arrest and increased expression of senescence-associated β-galactosidase, an enzymatic marker of senescence.

In contrast, BeSO(4) had no effect on RKO cells, even though Be(2+) uptake was similar for the two cell types.

Hazardous Substances Data Bank. BERYLLIUM SULFATE .

Hazardous Substances Data Bank. BERYLLIUM, ELEMENTAL .

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Oncogene. 1999 Dec 13;18(53):7644-55 [10618704.001]

[Cites] Radiat Res. 2005 Jan;163(1):53-62 [15606307.001]

[Cites] J Biol Chem. 2005 Jan 14;280(2):1186-92 [15533933.001]

[Cites] Int J Biochem Cell Biol. 2005 May;37(5):961-76 [15743671.001]

[Cites] Anal Biochem. 2005 Aug 15;343(2):329-34 [16004951.001]

[Cites] Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):976-81 [16418264.001]

[Cites] Biotechniques. 2006 Feb;40(2):173-7 [16526406.001]

[Cites] J Pharmacol Exp Ther. 2007 Jul;322(1):70-9 [17395767.001]

[Cites] Ann Allergy Asthma Immunol. 2008 Apr;100(4):333-7 [18450118.001]

[Cites] Int J Radiat Oncol Biol Phys. 2008 Aug 1;71(5):1485-95 [18640498.001]

[Cites] J Biomed Mater Res A. 2008 Sep 15;86(4):905-13 [18050301.001]

[Cites] Cell Cycle. 2008 Aug 15;7(16):2535-43 [18719376.001]

[Cites] Science. 2008 Sep 26;321(5897):1807-12 [18772396.001]

[Cites] Nature. 2008 Oct 23;455(7216):1061-8 [18772890.001]

[Cites] Mol Cell Biol. 2000 Mar;20(5):1713-22 [10669748.001]

[Cites] Mol Cell Biol. 2000 Apr;20(8):2803-8 [10733583.001]

[Cites] Cancer Lett. 2000 Dec 20;161(2):141-7 [11090962.001]

[Cites] FEBS Lett. 2001 Feb 16;490(3):117-22 [11223026.001]

[Cites] Gene Ther. 2000 Dec;7(24):2071-9 [11223987.001]

[Cites] Cancer Res. 2001 Feb 15;61(4):1493-9 [11245456.001]

[Cites] Toxicology. 2001 Mar 7;160(1-3):119-27 [11246132.001]

[Cites] Eur J Biochem. 2001 May;268(10):2784-91 [11358493.001]

[Cites] Mol Cell Biochem. 2001 Jun;222(1-2):69-76 [11678613.001]

[Cites] Oncogene. 2002 May 9;21(20):3207-12 [12082636.001]

[Cites] Mutat Res. 2003 Dec 10;533(1-2):99-105 [14643414.001]

[Cites] Mol Cell. 2004 May 21;14(4):501-13 [15149599.001]

[Cites] Radiat Res. 2004 May;161(5):504-10 [15161374.001]

[Cites] Cancer Res. 2004 Jun 1;64(11):3748-52 [15172978.001]

[Cites] Biochem J. 1968 Feb;106(4):811-20 [5637364.001]

[Cites] Chem Biol Interact. 1979 Jul;26(2):167-77 [455565.001]

[Cites] Environ Res. 1982 Feb;27(1):150-8 [7067673.001]

[Cites] Mutat Res. 1990 Mar;240(3):217-25 [2179717.001]

[Cites] Proc Natl Acad Sci U S A. 1993 May 1;90(9):3988-92 [8387205.001]

[Cites] Mol Cell Biol. 1993 Jul;13(7):4242-50 [8321226.001]

[Cites] Exp Cell Res. 1994 Mar;211(1):90-8 [8125163.001]

[Cites] Proc Natl Acad Sci U S A. 1995 Sep 26;92(20):9363-7 [7568133.001]

[Cites] BMJ. 1996 Apr 27;312(7038):1079 [8616417.001]

[Cites] Mutat Res. 1996 Nov 4;371(1-2):1-13 [8950345.001]

[Cites] Int J Radiat Oncol Biol Phys. 1997 Jan 1;37(1):145-54 [9054890.001]

[Cites] J Clin Pathol. 1997 Feb;50(2):106-9 [9155689.001]

[Cites] Mol Carcinog. 1997 Aug;19(4):243-53 [9290701.001]

[Cites] Cell. 1997 Oct 31;91(3):325-34 [9363941.001]

[Cites] Mol Cell Biol. 1998 Mar;18(3):1400-7 [9488455.001]

[Cites] Mol Cell Biol. 1998 Mar;18(3):1611-21 [9488478.001]

[Cites] EMBO J. 1998 Sep 1;17(17):5001-14 [9724636.001]

[Cites] J Biol Chem. 1999 Feb 5;274(6):3565-72 [9920903.001]

[Cites] Mol Cell Biol. 1999 Mar;19(3):2109-17 [10022898.001]

[Cites] Brain Pathol. 1999 Jul;9(3):469-79 [10416987.001]

[Cites] Mol Cell Biol. 2000 Feb;20(3):760-9 [10629032.001]

(PMID = 20549306.001).

[ISSN] 1572-8773

[Journal-full-title] Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine

[ISO-abbreviation] Biometals

[Language] ENG

[Grant] United States / NCRR NIH HHS / RR / P20 RR016464; United States / NCRR NIH HHS / RR / RR016464-077332; United States / NCRR NIH HHS / RR / P20 RR-016464; United States / NCRR NIH HHS / RR / P20 RR016464-077332

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / Tumor Suppressor Protein p53; 01UQ1KPC7E / beryllium sulfate; EC 3.2.1.23 / beta-Galactosidase; OW5102UV6N / Beryllium

[Other-IDs] NLM/ NIHMS223050; NLM/ PMC2976805

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Evaluation of MetriGenix custom 4D arrays applied for detection of breast cancer subtypes.

BACKGROUND: Previously, a total of five breast cancer subtypes have been identified based on variation in gene expression patterns.

In this study tumour samples from 27 breast cancer patients, previously subtyped by expression analysis using DNA microarrays, and four controls from normal breast tissue were included.

METHODS: We applied MetriGenix custom 4D arrays for the detection of previously defined molecular subtypes of breast cancer.

[MeSH-major] Breast Neoplasms / classification. Carcinoma / classification. Gene Expression Profiling / methods. Oligonucleotide Array Sequence Analysis / methods

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cytogenet Cell Genet. 1999;87(1-2):47-52 [10640810.001]

[Cites] Nature. 2000 Aug 17;406(6797):747-52 [10963602.001]

[Cites] Anal Chem. 2001 Jun 1;73(11):2412-20 [11403280.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Sep 11;98(19):10869-74 [11553815.001]

[Cites] Anal Chem. 2001 Dec 15;73(24):5777-83 [11791544.001]

[Cites] Cancer Res. 2005 Mar 15;65(6):2170-8 [15781628.001]

[Cites] Proc Natl Acad Sci U S A. 2002 May 14;99(10):6567-72 [12011421.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Jul 8;100(14):8418-23 [12829800.001]

[Cites] Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10393-8 [12917485.001]

[Cites] Clin Cancer Res. 2003 Nov 15;9(15):5582-8 [14654539.001]

[Cites] Mol Biol Cell. 2004 Jun;15(6):2523-36 [15034139.001]

[Cites] Expert Rev Mol Diagn. 2001 May;1(1):81-91 [11901803.001]

(PMID = 16536878.001).

[ISSN] 1471-2407

[Journal-full-title] BMC cancer

[ISO-abbreviation] BMC Cancer

[Language] eng

[Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ PMC1421426

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

DNA damage levels (none, low, medium and high) in the cervical epithelial cells of 31 women (10 with low grade squamous intraepithelial lesions [LSIL], 10 with high grade [HSIL] and 11 with no cervical lesion) were evaluated using the comet assay.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21434521.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Clinical Trial; Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

An automatic three-dimensional non-rigid registration scheme is proposed in this paper and applied to thoracic computed tomography (CT) data of patients with stage III non-small cell lung cancer (NSCLC).

[MeSH-major] Carcinoma, Non-Small-Cell Lung / radiography. Imaging, Three-Dimensional / methods. Lung Neoplasms / radiography. Pattern Recognition, Automated / methods. Radiographic Image Interpretation, Computer-Assisted / methods. Radiography, Thoracic / methods. Subtraction Technique

MedlinePlus Health Information. consumer health - Lung Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15854844.001).

[ISSN] 1361-8415

[Journal-full-title] Medical image analysis

[ISO-abbreviation] Med Image Anal

[Language] eng

[Publication-type] Clinical Trial; Controlled Clinical Trial; Journal Article

[Publication-country] England

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[MeSH-major] Angiography / methods. Carcinoma, Hepatocellular / diagnostic imaging. Imaging, Three-Dimensional / methods. Liver Neoplasms / diagnostic imaging. Tomography, X-Ray Computed / methods. User-Computer Interface

MedlinePlus Health Information. consumer health - CT Scans.

MedlinePlus Health Information. consumer health - Liver Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Med Image Anal. 2006 Jun;10(3):452-64 [15979375.001]

[Cites] Acad Radiol. 2007 Nov;14 (11):1325-40 [17964457.001]

(PMID = 20033612.001).

[ISSN] 1861-6429

[Journal-full-title] International journal of computer assisted radiology and surgery

[ISO-abbreviation] Int J Comput Assist Radiol Surg

[Language] eng

[Publication-type] Comparative Study; Journal Article

[Publication-country] Germany

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] HIV infection and the risk of cancers with and without a known infectious cause.

OBJECTIVE: To evaluate the risk of cancers with and without a known infectious cause in HIV-infected persons.

METHODS: Adult HIV-infected and matched HIV-uninfected members of Kaiser Permanente followed between 1996 and 2007 for incident AIDS-defining cancers (ADCs), infection-related non-AIDS-defining cancers (NADCs; anal squamous cell, vagina/vulva, Hodgkin's lymphoma, penis, liver, human papillomavirus-related oral cavity/pharynx, stomach) and infection-unrelated NADC (all other NADCs).

These results were largely influenced by anal squamous cell cancer and Hodgkin's lymphoma.

Among infection-unrelated NADCs, other anal, skin, other head and neck, and lung cancer rates were higher and prostate cancer rates lower in HIV-infected persons.

Among all infection-unrelated NADCs, the rate ratio decreased over time only for lung cancer (P = 0.007).

CONCLUSION: In comparison with those without HIV infection, HIV-infected persons are at particular risk for cancers with a known infectious cause, although the higher risk has decreased in the antiretroviral therapy era.

Cancers without a known infectious cause are modestly increased in HIV-infected persons compared with HIV-uninfected persons.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

COS Scholar Universe. author profiles.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Prog Exp Tumor Res. 1970;13:1-27 [4921480.001]

[Cites] AIDS. 2009 Jan 2;23(1):41-50 [19050385.001]

[Cites] Lancet. 1998 Jun 20;351(9119):1833-9 [9652666.001]

[Cites] AIDS. 1998 Aug 20;12(12):1459-64 [9727566.001]

[Cites] J Natl Cancer Inst. 1999 Feb 3;91(3):226-36 [10037100.001]

[Cites] AIDS. 1999 May 7;13(7):839-43 [10357384.001]

[Cites] J Natl Cancer Inst. 2005 Mar 16;97(6):425-32 [15770006.001]

[Cites] AIDS. 2009 Jan 28;23(3):385-93 [19114864.001]

[Cites] HIV Clin Trials. 2009 May-Jun;10(3):153-9 [19632954.001]

[Cites] J Hepatol. 2004 Jul;41(1):156-66 [15246224.001]

[Cites] JAMA. 2001 Apr 4;285(13):1736-45 [11277828.001]

[Cites] Int J Cancer. 2001 Dec 1;94(5):753-7 [11745473.001]

[Cites] J Acquir Immune Defic Syndr. 2001 Dec 15;28(5):422-8 [11744829.001]

[Cites] AIDS. 2002 May 3;16(7):993-1001 [11953465.001]

[Cites] AIDS. 2002 May 24;16(8):1155-61 [12004274.001]

[Cites] Clin Infect Dis. 2002 Oct 1;35(7):873-9 [12228825.001]

[Cites] J Acquir Immune Defic Syndr. 2004 Aug 1;36(4):978-85 [15220706.001]

[Cites] J Clin Oncol. 2006 Mar 20;24(9):1383-8 [16549832.001]

[Cites] Int J Cancer. 2006 Jun 15;118(12):3030-44 [16404738.001]

[Cites] Blood. 2006 Dec 1;108(12):3786-91 [16917006.001]

[Cites] AIDS. 2007 Jan 11;21(2):207-13 [17197812.001]

[Cites] Am J Epidemiol. 2007 May 15;165(10):1143-53 [17344204.001]

[Cites] Clin Infect Dis. 2007 Jul 1;45(1):103-10 [17554710.001]

[Cites] Lancet. 2007 Jul 7;370(9581):59-67 [17617273.001]

[Cites] AIDS. 2007 Sep 12;21(14):1957-63 [17721103.001]

[Cites] Curr Opin Oncol. 2007 Sep;19(5):446-51 [17762569.001]

[Cites] Eur J Cancer. 2007 Sep;43(14):2117-23 [17764927.001]

[Cites] J Clin Oncol. 2008 Feb 1;26(4):612-9 [18235120.001]

[Cites] Int J Cancer. 2008 Jul 1;123(1):187-94 [18435450.001]

[Cites] Ann Intern Med. 2008 May 20;148(10):728-36 [18490686.001]

[Cites] AIDS. 2008 Jun 19;22(10):1203-11 [18525266.001]

[Cites] Antivir Ther. 2008;13(3):455-60 [18572759.001]

[Cites] Curr HIV/AIDS Rep. 2008 Aug;5(3):140-9 [18627663.001]

[Cites] N Engl J Med. 1998 Apr 2;338(14):948-54 [9521982.001]

(PMID = 19741479.001).

[ISSN] 1473-5571

[Journal-full-title] AIDS (London, England)

[ISO-abbreviation] AIDS

[Language] ENG

[Grant] United States / NIAAA NIH HHS / AA / R01 AA016893; United States / NIAID NIH HHS / AI / K01 AI071725; United States / NIAID NIH HHS / AI / U01 AI069918-04; United States / NIAID NIH HHS / AI / K01 AI071725-03; United States / NIAID NIH HHS / AI / AI069918-04; United States / NIAID NIH HHS / AI / U01-AI069918; United States / NIAID NIH HHS / AI / K01AI071725; United States / NIAID NIH HHS / AI / AI071725-03; United States / NIAID NIH HHS / AI / U01 AI069918

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] England

[Other-IDs] NLM/ NIHMS198381; NLM/ PMC2863991

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Mayo Clinic office visit. Anal cancer. An interview with Heidi Nelson, M.D.

[MeSH-major] Anus Neoplasms / diagnosis. Anus Neoplasms / therapy. Health Knowledge, Attitudes, Practice. Patient Education as Topic

Genetic Alliance. consumer health - Anal Cancer.

MedlinePlus Health Information. consumer health - Anal Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19881450.001).

[ISSN] 1091-0220

[Journal-full-title] Mayo Clinic women's healthsource

[ISO-abbreviation] Mayo Clin Womens Healthsource

[Language] eng

[Publication-type] Interview

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

P-glycoprotein (P-gp) pumps multiple types of drugs out of the cell, using energy generated from ATP, and confers multidrug resistance (MDR) on cancer cells.

This study was designed to examine whether ZD6474 reverses P-gp-mediated MDR in cancer cells.

Here, we show that clinically achievable levels of ZD6474 reverse P-gp-mediated MDR of the P-gp-overexpressing cell lines derived from breast cancer, MCF-7/adriamycin (ADR), and human oral epidermoid carcinoma, KBV200 to ADR, docetaxel, and vinorelbine.

Our results suggest that ZD6474 is capable of reversing MDR in cancer cells by directly inhibiting the function of P-gp, a finding that may have clinical implications for ZD6474.

[MeSH-major] Cell Proliferation / drug effects. Drug Resistance, Multiple / drug effects. Drug Resistance, Neoplasm / drug effects. P-Glycoprotein / antagonists & inhibitors. Piperidines / pharmacology. Quinazolines / pharmacology

Hazardous Substances Data Bank. DOXORUBICIN .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] J Biol Chem. 2001 Mar 23;276(12):8657-64 [11121420.001]

[Cites] Mol Cancer Ther. 2006 Jul;5(7):1883-94 [16891475.001]

[Cites] EMBO J. 2001 Oct 15;20(20):5615-25 [11598005.001]

[Cites] J Bioenerg Biomembr. 2001 Dec;33(6):503-11 [11804192.001]

[Cites] Anal Biochem. 2002 Jun 1;305(1):106-14 [12018951.001]

[Cites] Annu Rev Biochem. 2002;71:537-92 [12045106.001]

[Cites] Biochim Biophys Acta. 2002 Jul 18;1587(2-3):318-25 [12084474.001]

[Cites] Clin Cancer Res. 2003 Apr;9(4):1546-56 [12684431.001]

[Cites] Oncogene. 2003 Oct 20;22(47):7340-58 [14576842.001]

[Cites] Mol Pharmacol. 2004 Jun;65(6):1485-95 [15155841.001]

[Cites] Biochem Pharmacol. 2004 Sep 1;68(5):843-55 [15294447.001]

[Cites] Blood. 1991 Sep 1;78(5):1385-7 [1878599.001]

[Cites] Cancer Res. 1994 Jan 1;54(1):152-8 [7903202.001]

[Cites] Biochem J. 1996 Jul 15;317 ( Pt 2):515-22 [8713080.001]

[Cites] Ann Oncol. 2005 May;16 Suppl 4:iv61-68 [15923432.001]

[Cites] Br J Cancer. 2005 Jun;92 Suppl 1:S6-13 [15928657.001]

[Cites] Cancer Res. 2005 Jun 1;65(11):4852-60 [15930306.001]

[Cites] Ann Oncol. 2005 Aug;16(8):1391-7 [15905307.001]

[Cites] Cancer Res. 2005 Aug 1;65(15):6943-9 [16061679.001]

[Cites] Lung Cancer. 2005 Sep;49(3):337-43 [15955594.001]

[Cites] Semin Oncol. 2006 Feb;33(1 Suppl 1):S9-16 [16472704.001]

[Cites] Cell Mol Life Sci. 2001 Jun;58(7):931-59 [11497241.001]

(PMID = 17912240.001).

[ISSN] 0007-0920

[Journal-full-title] British journal of cancer

[ISO-abbreviation] Br. J. Cancer

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] England

[Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 0 / P-Glycoprotein; 0 / Piperidines; 0 / Quinazolines; 1N3CZ14C5O / Rhodamine 123; 80168379AG / Doxorubicin; EC 3.6.1.- / Adenosine Triphosphatases

[Other-IDs] NLM/ PMC2360411

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992-2003.

BACKGROUND: Persons who are HIV-infected may be at higher risk for certain types of cancer than the general population.

OBJECTIVE: To compare cancer incidence among HIV-infected persons with incidence in the general population from 1992 to 2003.

PATIENTS: 54,780 HIV-infected persons in the Adult and Adolescent Spectrum of HIV Disease Project (47,832 patients) and the HIV Outpatient Study (6948 patients), who contributed 157,819 person-years of follow-up from 1992 to 2003, and 334,802,121 records from the Surveillance, Epidemiology, and End Results program of 13 geographically defined, population-based, central cancer registries.

MEASUREMENTS: Standardized rate ratios (SRRs) to compare cancer incidence in the HIV-infected population with standardized cancer incidence in the general population.

RESULTS: The incidence of the following types of non-AIDS-defining cancer was significantly higher in the HIV-infected population than in the general population: anal (SRR, 42.9 [95% CI, 34.1 to 53.3]), vaginal (21.0 [CI, 11.2 to 35.9]), Hodgkin lymphoma (14.7 [CI, 11.6 to 18.2]), liver (7.7 [CI, 5.7 to 10.1]), lung (3.3 [CI, 2.8 to 3.9]), melanoma (2.6 [CI, 1.9 to 3.6]), oropharyngeal (2.6 [CI, 1.9 to 3.4]), leukemia (2.5 [CI, 1.6 to 3.8]), colorectal (2.3 [CI, 1.8 to 2.9]), and renal (1.8 [CI, 1.1 to 2.7]).

The incidence of prostate cancer was significantly lower among HIV-infected persons than the general population (SRR, 0.6 [CI, 0.4 to 0.8]).

Only the relative incidence of anal cancer increased over time.

LIMITATIONS: Lower ascertainment of cancer in the HIV cohorts may result in a potential bias to underestimate rate disparities.

Tobacco use as a risk factor and the effect of changes in cancer screening practices could not be evaluated.

CONCLUSION: The incidence of many types of non-AIDS-defining cancer was higher among HIV-infected persons than among the general population from 1992 to 2003.

[MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Incidence. Male. Middle Aged. Observation. Prospective Studies. Risk Factors. Tobacco Use Disorder / complications. United States / epidemiology

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - HIV/AIDS.

MedlinePlus Health Information. consumer health - HIV/AIDS in Women.

ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

The Lens. Cited by Patents in .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[SummaryForPatientsIn] Ann Intern Med. 2008 May 20;148(10):I46 [18490669.001]

(PMID = 18490686.001).

[ISSN] 1539-3704

[Journal-full-title] Annals of internal medicine

[ISO-abbreviation] Ann. Intern. Med.

[Language] eng

[Grant] United States / PHS HHS / / 200-2006-18797

[Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.

[Publication-country] United States

[Investigator] Thompson M; Sinclair E; Cohen D; Davidson A; Rietmeijer C; Garland W; Wohl A; Morse A; Wotring L; Mokotoff E; Murrill C; Bernard MA; Amill A; de los Angeles Gomez M; Miranda S; Buskin S; Barash E; Odem S; Keiser P; Awosika-Olumo A; Wood KC; Baker RK; Palella FJ; Chmiel JS; Cheley J; Lichtenstein KA; Greenberg KS; Young B; Widick B; Stewart C; Zellner P; Yangco BG; Halkias K; Ward DJ; Fiorentino CA; Ording-Bauer L; Kelly R; Esteves J; Tedaldi EM; Christian R; Ruley F; Marzouk JB; Phelps RT; Rachel M; McCabe RE; Rachel M; Novak RM; Uy JP; Wendrow A

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Jasmine tea consumption and upper gastrointestinal cancer in China.

INTRODUCTION: Epidemiological data on green/jasmine tea and esophageal as well as gastric cancer are limited and inconclusive.

METHODS: In order to study the effect of jasmine tea in upper gastrointestinal (UGI) cancers, we evaluated 600 esophageal squamous cell carcinoma (ESCC), 598 gastric cardia cancer (GCA), and 316 gastric non-cardia cancer (GNCA) cases and 1,514 age-, gender-, and neighborhood-matched controls.

CONCLUSION: Overall, we found no evidence for a protective effect of tea in esophageal or gastric cancer.

Further studies of the potential effects of thermal damage, tea quality, and water quality on UGI cancers are suggested.

[MeSH-major] Carcinoma, Squamous Cell / etiology. Drinking Behavior / physiology. Gastrointestinal Neoplasms / etiology. Jasminum. Plant Preparations. Tea

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. Green tea .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Analyst. 1998 Oct;123(10):2145-8 [10209900.001]

[Cites] Curr Drug Metab. 2006 Oct;7(7):755-809 [17073579.001]

[Cites] Int J Cancer. 2005 Jan 20;113(3):456-63 [15455378.001]

[Cites] Food Chem Toxicol. 2005 Jan;43(1):41-8 [15582194.001]

[Cites] Carcinogenesis. 2005 Jan;26(1):193-200 [15498792.001]

[Cites] J Agric Food Chem. 2004 Dec 29;52(26):8268-71 [15612828.001]

[Cites] Mol Nutr Food Res. 2007 Jan;51(1):116-34 [17195249.001]

[Cites] Eur J Gastroenterol Hepatol. 2007 Feb;19(2):171-6 [17273005.001]

[Cites] Mayo Clin Proc. 2007 Jun;82(6):725-32 [17550753.001]

[Cites] J Chromatogr B Analyt Technol Biomed Life Sci. 2007 Jun 15;853(1-2):154-62 [17400037.001]

[Cites] Phytomedicine. 2007 Aug;14(7-8):551-5 [17092697.001]

[Cites] J Cell Biochem. 2008 Feb 1;103(2):509-19 [17570133.001]

[Cites] J Clin Gastroenterol. 2008 May-Jun;42(5):610-9 [18364578.001]

[Cites] Int J Cancer. 2009 Feb 1;124(3):670-7 [18973231.001]

[Cites] BMJ. 2009;338:b929 [19325180.001]

[Cites] Nat Rev Cancer. 2009 Jun;9(6):429-39 [19472429.001]

[Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1999 Apr;20(2):95-7 [10682542.001]

[Cites] Int J Cancer. 2000 Nov 15;88(4):658-64 [11058886.001]

[Cites] Br J Cancer. 2001 Nov 30;85(11):1667-70 [11742485.001]

[Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 2001 Dec;22(6):442-5 [11851060.001]

[Cites] Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:159-72 [11890101.001]

[Cites] Anal Sci. 2002 Mar;18(3):313-8 [11918191.001]

[Cites] FASEB J. 2002 Sep;16(11):1463-4 [12205049.001]

[Cites] World J Gastroenterol. 2003 Jun;9(6):1187-90 [12800221.001]

[Cites] Chemosphere. 2003 Sep;52(9):1475-82 [12867178.001]

[Cites] Asian Pac J Cancer Prev. 2003 Apr-Jun;4(2):119-24 [12875624.001]

[Cites] Zhonghua Yu Fang Yi Xue Za Zhi. 2003 May;37(3):171-3 [12880562.001]

[Cites] Carcinogenesis. 2003 Aug;24(8):1369-78 [12819184.001]

[Cites] Cancer Res. 2003 Nov 15;63(22):7563-70 [14633667.001]

[Cites] Mutat Res. 2004 Mar 22;547(1-2):55-62 [15013699.001]

[Cites] Nat Rev Cancer. 2004 Aug;4(8):630-7 [15286742.001]

[Cites] Gut. 1972 Jan;13(1):24-30 [5060664.001]

[Cites] Int J Cancer. 1974 Mar 15;13(3):291-303 [4822104.001]

[Cites] Sci Sin. 1975 Jan-Feb;18(1):131-48 [1145176.001]

[Cites] Br J Cancer. 1979 Mar;39(3):293-309 [465299.001]

[Cites] Biomed Environ Sci. 1990 Mar;3(1):35-42 [2331325.001]

[Cites] Zhonghua Liu Xing Bing Xue Za Zhi. 1991 Aug;12(4):200-4 [1934041.001]

[Cites] Biomed Environ Sci. 1991 Sep;4(3):225-31 [1764211.001]

[Cites] Prev Med. 1992 May;21(3):385-91 [1615000.001]

[Cites] Int J Cancer. 1994 Apr 1;57(1):38-46 [8150539.001]

[Cites] J Natl Cancer Inst. 1994 Jun 1;86(11):855-8 [8182766.001]

[Cites] Am J Ind Med. 1995 May;27(5):749-57 [7611309.001]

[Cites] J Epidemiol. 1998 Oct;8(4):235-43 [9816815.001]

[Cites] Am J Ind Med. 1999 Mar;35(3):272-80 [9987560.001]

[Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]

[Cites] J Epidemiol. 2005 Jun;15 Suppl 2:S109-12 [16127221.001]

[Cites] Cancer Res. 2005 Sep 1;65(17):8049-56 [16140980.001]

[Cites] Environ Monit Assess. 2005 Aug;107(1-3):399-406 [16418925.001]

[Cites] Environ Sci Technol. 2006 Feb 15;40(4):1133-8 [16572766.001]

[Cites] J Agric Food Chem. 2006 Jun 14;54(12):4350-4 [16756366.001]

[Cites] World J Gastroenterol. 2006 Jul 7;12(25):4033-7 [16810754.001]

[Cites] J Food Prot. 2006 Aug;69(8):2024-8 [16924937.001]

[Cites] J Epidemiol. 2006 Sep;16(5):185-92 [16951537.001]

[Cites] Asian Pac J Cancer Prev. 2006 Jul-Sep;7(3):375-80 [17059325.001]

[Cites] Int J Cancer. 2005 Jan 20;113(3):475-82 [15455377.001]

(PMID = 19597950.001).

[ISSN] 1573-7225

[Journal-full-title] Cancer causes & control : CCC

[ISO-abbreviation] Cancer Causes Control

[Language] eng

[Grant] United States / Intramural NIH HHS / / Z01 CP000185-03

[Publication-type] Journal Article; Research Support, N.I.H., Intramural

[Publication-country] Netherlands

[Chemical-registry-number] 0 / Plant Preparations; 0 / Tea

[Other-IDs] NLM/ NIHMS339598; NLM/ PMC3236106

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Mainstream uses for photodynamic therapy (PDT) in dermatology include nonmelanoma skin cancer and its precursors, acne vulgaris, photorejuvenation, and hidradenitis suppurativa.

Many other dermatologic entities have been treated with PDT, including psoriasis, lichen planus, lichen sclerosus, scleroderma, cutaneous T cell lymphoma, alopecia areata, verruca vulgaris, Darier's disease and tinea infections.

Nondermatologic applications include anal and vulva carcinoma, palliation of metastatic breast cancer to skin, Barrett's esophagus, and macular degeneration of the retina.

PDT also has found to be useful in immunologic and inflammatory disorders, neoplasias other than skin cancer, and infections.

[MeSH-major] Infection / drug therapy. Neoplasms / drug therapy. Photochemotherapy. Skin Diseases / drug therapy

MedlinePlus Health Information. consumer health - Cancer Chemotherapy.

MedlinePlus Health Information. consumer health - Skin Conditions.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 17126748.001).

[ISSN] 0733-8635

[Journal-full-title] Dermatologic clinics

[ISO-abbreviation] Dermatol Clin

[Language] eng

[Publication-type] Journal Article; Review

[Publication-country] United States

[Number-of-references] 59

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

Moderate cytotoxicity was observed with the human colon carcinoma cell line HCT-116, but no cytotoxic effect was noted with cultured RAW cells.

COS Scholar Universe. author profiles.

Hazardous Substances Data Bank. NITRIC OXIDE .

SILVA. SILVA SSU Database .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Cell Cycle. 2008 Apr 15;7(8):1020-35 [18414053.001]

[Cites] J Am Chem Soc. 2008 Apr 2;130(13):4507-16 [18331040.001]

[Cites] Phytochemistry. 2002 Nov;61(6):693-8 [12423891.001]

[Cites] Methods Enzymol. 2008;441:329-38 [18554543.001]

[Cites] J Antibiot (Tokyo). 1999 Oct;52(10):873-9 [10604756.001]

[Cites] Annu Rev Immunol. 2000;18:621-63 [10837071.001]

[Cites] Biol Reprod. 2002 Aug;67(2):668-73 [12135912.001]

[Cites] Anal Biochem. 1982 Oct;126(1):131-8 [7181105.001]

[Cites] J Nat Prod. 1992 May;55(5):613-9 [1517734.001]

[Cites] Phytochemistry. 1994 Nov;37(5):1301-3 [7765754.001]

[Cites] Planta Med. 2006 Feb;72(3):255-60 [16534731.001]

[Cites] J Nat Prod. 2006 Mar;69(3):421-4 [16562850.001]

[Cites] Eur J Cancer. 2006 Apr;42(6):779-84 [16530406.001]

[Cites] Cell Death Differ. 2006 May;13(5):738-47 [16485028.001]

[Cites] Nat Chem Biol. 2006 Dec;2(12):666-73 [17108984.001]

[Cites] Expert Opin Ther Targets. 2007 Feb;11(2):133-44 [17227230.001]

[Cites] Cancer Sci. 2007 Mar;98(3):268-74 [17270016.001]

[Cites] Appl Environ Microbiol. 2007 Feb;73(4):1146-52 [17158611.001]

[Cites] Appl Environ Microbiol. 2007 May;73(10):3272-82 [17400789.001]

[Cites] Nat Prod Rep. 2008 Feb;25(1):35-94 [18250897.001]

[ErratumIn] J Nat Prod. 2010 Apr 23;73(4):796

(PMID = 19117399.001).

[ISSN] 1520-6025

[Journal-full-title] Journal of natural products

[ISO-abbreviation] J. Nat. Prod.

[Language] ENG

[Grant] United States / NCI NIH HHS / CA / P01 CA048112; United States / NCI NIH HHS / CA / R37 CA044848; United States / NCI NIH HHS / CA / CA048112-150007; United States / NCI NIH HHS / CA / P01 CA048112-150007; United States / NCI NIH HHS / CA / R37 CA044848-22; United States / NCI NIH HHS / CA / P01 CA48112; United States / NCI NIH HHS / CA / CA044848-22; United States / FIC NIH HHS / TW / U01 TW007401; United States / FIC NIH HHS / TW / U01-TW007401-01

[Publication-type] Journal Article; Research Support, N.I.H., Extramural

[Publication-country] United States

[Chemical-registry-number] 0 / Anti-Inflammatory Agents, Non-Steroidal; 0 / Depsipeptides; 0 / Lipopolysaccharides; 0 / NF-kappa B; 0 / Tumor Necrosis Factor-alpha; 0 / arenamide A; 0 / arenamide B; 0 / arenamide C; 31C4KY9ESH / Nitric Oxide; K7Q1JQR04M / Dinoprostone

[Other-IDs] NLM/ NIHMS91488; NLM/ PMC2837138

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] High resolution anoscopy in the planned staged treatment of anal squamous intraepithelial lesions in HIV-negative patients.

Anal dysplasia (low-grade squamous intraepithelial lesions, LSIL; high-grade squamous intraepithelial lesions, HSIL) is a challenging disease for the surgeon.

We reviewed 42 patients that underwent high-resolution anoscopy (HRA)-targeted surgical therapy of anal dysplasia in the past 10 years.

Patients were followed up in the Anal Neoplasia Clinic with physical examination, cytology, HRA, and biopsy if indicated.

Progression to HSIL was seen in one patient with LSIL and to squamous cell carcinoma in one patient with HSIL despite therapy.

HRA-targeted surgical therapy coupled with surveillance and re-treatment with office-based therapies offered an effective method in controlling anal dysplasia in the immunocompetent patient.

Morbidity is minimal, and our progression to cancer rate is low (2.4%).

[MeSH-major] Anus Neoplasms / surgery. Carcinoma in Situ / surgery. Carcinoma, Squamous Cell / surgery

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Dis Colon Rectum. 2006 Jan;49(1):36-40 [16283561.001]

[Cites] Dis Colon Rectum. 2007 May;50(5):565-75 [17380365.001]

[Cites] Dis Colon Rectum. 1987 Oct;30(10):782-5 [3652891.001]

[Cites] Dis Colon Rectum. 2006 Jan;49(1):126 [16222485.001]

[Cites] Arch Surg. 2004 Mar;139(3):259-61 [15006881.001]

[Cites] Dis Colon Rectum. 2005 May;48(5):1042-54 [15868241.001]

[Cites] Dis Colon Rectum. 2001 May;44(5):690-8 [11357031.001]

[Cites] Br J Surg. 1999 Aug;86(8):1063-6 [10460644.001]

[Cites] Surg Oncol Clin N Am. 2004 Apr;13(2):355-73 [15137962.001]

[Cites] Arch Dermatol. 2006 Nov;142(11):1438-44 [17116834.001]

[Cites] Dis Colon Rectum. 1997 Aug;40(8):912-8 [9269807.001]

[Cites] Dis Colon Rectum. 1997 Aug;40(8):919-28 [9269808.001]

[Cites] ANZ J Surg. 2006 Aug;76(8):715-7 [16916390.001]

[Cites] Dis Colon Rectum. 2002 Apr;45(4):453-8 [12006924.001]

[Cites] Dis Colon Rectum. 2004 Oct;47(10):1655-60; discussion 1660-1 [15540295.001]

[Cites] Br J Surg. 2005 Sep;92(9):1133-6 [16044425.001]

[Cites] Dis Colon Rectum. 1997 Nov;40(11):1286-93 [9369101.001]

(PMID = 17710507.001).

[ISSN] 1091-255X

[Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract

[ISO-abbreviation] J. Gastrointest. Surg.

[Language] eng

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Intranuclear cytoplasmic inclusions and nuclear grooves in fine needle aspiration smears of papillary thyroid carcinoma and its variants: advantage of the count under an oil-immersion objective over a high-power objective.

OBJECTIVE: To determine the advantage of examining fine needle aspiration (FNA) smears of papillary thyroid carcinoma (PTC) under a 100 x oil-immersion objective, which is capable of optically sectioning the cells.

STUDY DESIGN: Two hundred neoplastic cells were counted under a high-power (40x) objective as well as oil-immersion (100x) objective in 54 PTC cases classified into variants: 14 follicular neoplasms, 8 Hürthle cell neoplasms, 5 medullary thyroid carcinomas and 9 hyperplastic lesions.

In PTC cases, the mean cell count, 10.1 (+/- 1.75 SE) with INCIs, under the oil-immersion objective was significantly higher than the count, 6.1 (+/- 1.32 SE), under the high-power objective (p = 0.023).

In PTC the mean cell count, 88.0 (+/- 4.96 SE), with grooved nuclei under the oil-immersion objective was also significantly higher than the count, 69.5 (+/- 4.87 SE), under the high-power objective (p = 0.010).

In PTC the mean cell counts with INCIs as well as grooved nuclei under the oil-immersion objective were significantly higher than those of follicular neoplasms, Hürthle cell neoplasms, medullary carcinoma and hyperplastic lesions.

MedlinePlus Health Information. consumer health - Thyroid Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 15913201.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Evaluation Studies; Journal Article

[Publication-country] United States

[Chemical-registry-number] 0 / Oils

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Screening for HIV-associated anal cancer: correlation of HPV genotypes, p16, and E6 transcripts with anal pathology.

BACKGROUND: HIV-positive men with a history of anal-receptive intercourse are at risk for anal cancer.

We determined whether human papilloma virus (HPV) biomarkers were correlated with anal pathology in these men.

The number of HPV genotypes per anal swab was higher for anal intraepithelial neoplasia (AIN) 2/3 than for normal or AIN 1 histology [median, 5 types (interquartile range) (IQR), 3-7 versus 3.5 (IQR), 2-6; P = 0.0005].

CONCLUSIONS: The presence of high-grade anal pathology (AIN 2/3) in HIV-positive men was associated with multiple HPV genotypes, HPV genotypes 16 and 31, and HPV 16 viral load.

[MeSH-major] Alphapapillomavirus / genetics. Anus Neoplasms / epidemiology. Carcinoma in Situ / epidemiology. Genes, p16. HIV Seropositivity / virology. Oncogene Proteins, Viral / genetics. Repressor Proteins / genetics

Genetic Alliance. consumer health - Anal Cancer.

Genetic Alliance. consumer health - HIV.

MedlinePlus Health Information. consumer health - Anal Cancer.

COS Scholar Universe. author profiles.

HIV InSite. treatment guidelines - Human Herpesvirus-8 .

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19567510.001).

[ISSN] 1538-7755

[Journal-full-title] Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology

[ISO-abbreviation] Cancer Epidemiol. Biomarkers Prev.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / DNA, Viral; 0 / E6 protein, Human papillomavirus type 16; 0 / Oncogene Proteins, Viral; 0 / Repressor Proteins

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

The development of proteomics technologies has lead to a great deal of effort being focused on the identification of biomarkers for cancers.

Although many papers have reported candidate biomarkers for hepatocellular carcinomas (HCCs) in particular, so far none of these candidate biomarkers have been used either for diagnosis or therapy intreating patients.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 21160973.001).

[ISSN] 1948-5182

[Journal-full-title] World journal of hepatology

[ISO-abbreviation] World J Hepatol

[Language] eng

[Publication-type] Journal Article

[Publication-country] China

[Other-IDs] NLM/ PMC2999271

[Keywords] NOTNLM ; Biomarker / Hepatocellular carcinoma / Mass spectrometry / Proteomics / Two-dimensional polyacrylamide gel electrophoresis

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

OBJECTIVES: Oral cancer is the fifth most frequent cancer worldwide and India has recorded the highest incidence (40-50%) of oral malignancy.

METHODS: Male Syrian golden hamsters painted with 0.5% 7,12-dimethylbenz[a]anthracene on the buccal pouches and developed oral squamous cell carcinoma were included in this study.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 22043357.001).

[ISSN] 2070-5204

[Journal-full-title] Oman medical journal

[ISO-abbreviation] Oman Med J

[Language] eng

[Publication-type] Journal Article

[Publication-country] Oman

[Other-IDs] NLM/ PMC3191666

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions.

The association of HPV DNA with several different ano-genital cancers other than cervical has been reported for the vulva, vagina, anus and penis.

HPV DNA has also been identified in head and neck cancers in the oral cavity, the oropharynx and the larynx in both sexes.

In men, 80-85% of anal cancers and close to 50% of penile cancers are associated with HPV infection.

In women, HPV DNA is prevalent in 36-40% vulvar cancer cases and close to 90% of vaginal cancers.

Among HPV DNA positive ano-genital cancer cases, HPV-16 is the most frequently found followed distantly by HPV-18.

We summarize the evidence linking HPV in the epidemiology and etiology of cancers of the vulva, vagina, anus and oropharynx and present recent estimates of the burden of and HPV type distribution in genital warts and in cases of HPV infection of the airways.

[MeSH-minor] Anus Neoplasms / virology. Female. Humans. Male. Papillomaviridae / immunology. Papillomaviridae / pathogenicity. Respiratory Tract Infections / epidemiology. Respiratory Tract Infections / virology. Uterine Cervical Diseases / epidemiology. Uterine Cervical Diseases / virology

MedlinePlus Health Information. consumer health - Genital Warts.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 18847554.001).

[ISSN] 0264-410X

[Journal-full-title] Vaccine

[ISO-abbreviation] Vaccine

[Language] eng

[Grant] United States / NCI NIH HHS / CA / R01 CA098803

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review

[Publication-country] Netherlands

[Number-of-references] 91

[Other-IDs] NLM/ NIHMS73638; NLM/ PMC4366004

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Renal papillary carcinoma classification into subtypes may be reproduced by nuclear morphometry.

OBJECTIVE: To analyze relationships between nuclear features of papillary renal cell carcinoma (PapRCC) subtypes.

MedlinePlus Health Information. consumer health - Kidney Cancer.

[Email] Email this result item

Email the results to the following email address:   [X] Close

(PMID = 19402388.001).

[ISSN] 0884-6812

[Journal-full-title] Analytical and quantitative cytology and histology

[ISO-abbreviation] Anal. Quant. Cytol. Histol.

[Language] ENG

[Publication-type] Journal Article

[Publication-country] United States

   

[Fulltext service] Download fulltext PDF of this article and others, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Lysophosphatidic acid-induced transcriptional profile represents serous epithelial ovarian carcinoma and worsened prognosis.

Malignant ascites fluid is rich in LPA, and LPA receptors are aberrantly expressed by ovarian cancer cells, implicating LPA in the initiation and progression of ovarian cancer.

However, there is an absence of systematic data critically analyzing the transcriptional changes induced by LPA in ovarian cancer.

METHODOLOGY AND PRINCIPAL FINDINGS: In this study, gene expression profiling was used to examine LPA-mediated transcription by exogenously adding LPA to human epithelial ovarian cancer cells for 24 h to mimic long-term stimulation in the tumor microenvironment.

The resultant transcriptional profile comprised a 39-gene signature that closely correlated to serous epithelial ovarian carcinoma.

Hierarchical clustering of ovarian cancer patient specimens demonstrated that the signature is associated with worsened prognosis.

They have a higher frequency of stage IIIc serous carcinoma and a greater proportion is deceased.

Among the 39-gene signature, a group of seven genes associated with cell adhesion recapitulated the results.

Out of those seven, claudin-1, an adhesion molecule and phenotypic epithelial marker, is the only independent biomarker of serous epithelial ovarian carcinoma.

Knockdown of claudin-1 expression in ovarian cancer cells reduces LPA-mediated cellular adhesion, enhances suspended cells and reduces LPA-mediated migration.

CONCLUSIONS: The data suggest that transcriptional events mediated by LPA in the tumor microenvironment influence tumor progression through modulation of cell adhesion molecules like claudin-1 and, for the first time, report an LPA-mediated expression signature in ovarian cancer that predicts a worse prognosis.

[MeSH-minor] Blotting, Western. Cell Adhesion / genetics. Cell Adhesion / physiology. Cell Line, Tumor. Cell Proliferation. Cell Survival / genetics. Cell Survival / physiology. Claudin-1. Cluster Analysis. Female. Gene Expression Regulation, Neoplastic / genetics. Humans. Membrane Proteins / genetics. Oligonucleotide Array Sequence Analysis. Polymerase Chain Reaction

MedlinePlus Health Information. consumer health - Ovarian Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Clin Cancer Res. 1999 Nov;5(11):3704-10 [10589790.001]

[Cites] Mol Oncol. 2008 Jun;2(1):54-69 [19081821.001]

[Cites] Anal Biochem. 2001 Mar15;290(2):302-13 [11237333.001]

[Cites] Proc Natl Acad Sci U S A. 2001 Apr 24;98(9):5116-21 [11309499.001]

[Cites] Gynecol Oncol. 2001 May;81(2):291-300 [11330965.001]

[Cites] Bioinformatics. 2001 Jun;17(6):520-5 [11395428.001]

[Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]

[Cites] Biochim Biophys Acta. 2002 May 23;1582(1-3):257-64 [12069836.001]

[Cites] Cancer Res. 2003 Mar 1;63(5):1073-82 [12615725.001]

[Cites] Nat Rev Cancer. 2003 Aug;3(8):582-91 [12894246.001]

[Cites] Hematol Oncol Clin North Am. 2003 Aug;17(4):909-25, vii [12959182.001]

[Cites] Genome Biol. 2003;4(10):R70 [14519205.001]

[Cites] Nucleic Acids Res. 2003 Dec 15;31(24):e154 [14654707.001]

[Cites] Endocrinology. 2004 Jun;145(6):2929-40 [14988385.001]

[Cites] J Cell Biochem. 2004 Aug 15;92(6):1115-40 [15258897.001]

[Cites] Arterioscler Thromb. 1993 Nov;13(11):1662-7 [8218108.001]

[Cites] Biochem J. 1998 Mar 15;330 ( Pt 3):1107-14 [9494074.001]

[Cites] Ann Oncol. 1998 Apr;9(4):437-42 [9636836.001]

[Cites] Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14863-8 [9843981.001]

[Cites] Gynecol Oncol. 1998 Dec;71(3):364-8 [9887232.001]

[Cites] Proc Natl Acad Sci U S A. 1999 May 25;96(11):6249-54 [10339573.001]

[Cites] Nat Rev Cancer. 2005 May;5(5):355-66 [15864277.001]

[Cites] Oncogene. 2005 Jul 7;24(29):4672-87 [15940270.001]

[Cites] J Clin Invest. 2005 Jul;115(7):1765-76 [15965503.001]

[Cites] Cancer Res. 2005 Nov 1;65(21):9603-6 [16266975.001]

[Cites] Cancer Res. 2005 Nov 15;65(22):10602-12 [16288054.001]

[Cites] Cancer Res. 2006 Feb 1;66(3):1354-62 [16452189.001]

[Cites] Cancer Res. 2006 Mar 1;66(5):2740-8 [16510595.001]

[Cites] Matrix Biol. 2006 May;25(4):223-31 [16503403.001]

[Cites] J Biol Chem. 2006 Aug 11;281(32):22786-93 [16782709.001]

[Cites] Eur J Cancer. 2006 Nov;42(16):2846-54 [16996261.001]

[Cites] Gynecol Oncol. 2006 Nov;103(2):591-8 [16797678.001]

[Cites] CA Cancer J Clin. 2007 Jan-Feb;57(1):43-66 [17237035.001]

[Cites] Am J Obstet Gynecol. 2007 Mar;196(3):245.e1-11 [17346539.001]

[Cites] Am J Clin Pathol. 2007 Jun;127(6):928-37 [17509990.001]

[Cites] Expert Rev Mol Med. 2007;9(28):1-18 [17935635.001]

[Cites] Hum Pathol. 2008 May;39(5):747-57 [18439941.001]

[Cites] Adv Exp Med Biol. 2008;617:23-40 [18497028.001]

[Cites] Clin Cancer Res. 2008 Aug 15;14(16):5198-208 [18698038.001]

[Cites] Biochim Biophys Acta. 2008 Sep;1781(9):547-57 [18501205.001]

[Cites] J Natl Cancer Inst. 2008 Nov 19;100(22):1630-42 [19001604.001]

[Cites] Clin Cancer Res. 2000 Jun;6(6):2482-91 [10873103.001]

(PMID = 19440550.001).

[ISSN] 1932-6203

[Journal-full-title] PloS one

[ISO-abbreviation] PLoS ONE

[Language] eng

[Grant] United States / NCI NIH HHS / CA / P01 CA099031; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA098258

[Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't

[Publication-country] United States

[Chemical-registry-number] 0 / CLDN1 protein, human; 0 / Claudin-1; 0 / Lysophospholipids; 0 / Membrane Proteins; 22002-87-5 / lysophosphatidic acid

[Other-IDs] NLM/ PMC2679144

   

[Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

[Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.

[Title] Quantum dot-induced epigenetic and genotoxic changes in human breast cancer cells.

We examined here the epigenomic and genotoxic response to cadmium telluride quantum dots (QDs) in human breast carcinoma cells.

Consequential decrease in cell viability was in part prevented by the p53 inhibitor pifithrin-alpha, suggesting that p53 translocation contributes to QD-induced cytotoxicity.

[MeSH-minor] Acetylation. Animals. Apoptosis Regulatory Proteins / genetics. Apoptosis Regulatory Proteins / metabolism. Cell Line, Tumor. Cell Nucleus / metabolism. Cell Nucleus / ultrastructure. Chromatin / metabolism. Chromatin / ultrastructure. Gene Expression Regulation, Neoplastic. Histones / metabolism. Humans. Mitochondria / ultrastructure. Models, Biological. PC12 Cells. Phosphorylation. Protein Processing, Post-Translational. Protein Transport. RNA, Messenger / genetics. RNA, Messenger / metabolism. Rats. Tumor Suppressor Protein p53 / metabolism

Genetic Alliance. consumer health - Breast Cancer.

MedlinePlus Health Information. consumer health - Breast Cancer.

COS Scholar Universe. author profiles.

NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

[Email] Email this result item

Email the results to the following email address:   [X] Close

[Cites] Carcinogenesis. 2006 Jun;27(6):1121-5 [16699174.001]

[Cites] Eur J Pharm Biopharm. 2007 Mar;65(3):270-81 [17027243.001]

[Cites] Cancer Biol Ther. 2006 Sep;5(9):1199-205 [17110788.001]

[Cites] FEBS Lett. 2007 Jul 31;581(19):3743-8 [17433304.001]

[Cites] J Invest Dermatol. 2007 Jan;127(1):143-53 [16902417.001]

[Cites] Cell Death Differ. 2005 Nov;12 Suppl 2:1528-34 [16247500.001]

[Cites] Biomaterials. 2006 Mar;27(9):1679-87 [16318871.001]

[Cites] Environ Health Perspect. 2006 Feb;114(2):165-72 [16451849.001]

[Cites] Free Radic Biol Med. 2004 Sep 1;37(5):582-93 [15288116.001]

[Cites] J Nanobiotechnology. 2006 Oct 20;4:10 [17054792.001]

[Cites] J Mol Med (Berl). 2005 May;83(5):377-85 [15688234.001]

[Cites] Science. 2006 Feb 3;311(5761):622-7 [16456071.001]

[Cites] J Biol Chem. 2006 May 12;281(19):13540-7 [16531610.001]

[Cites] Int J Mol Med. 1998 Jun;1(6):1001-6 [9852638.001]

[Cites] Nature. 2000 Jan 6;403(6765):41-5 [10638745.001]

[Cites] J Nanobiotechnology. 2007 Feb 12;5:1 [17295922.001]

[Cites] J Neurooncol. 2000;46(2):125-33 [10894365.001]

[Cites] Nat Cell Biol. 2003 Apr;5(4):320-9 [12652308.001]

[Cites] Oncogene. 2006 Aug 7;25(34):4697-705 [16892083.001]

[Cites] Langmuir. 2007 Feb 13;23 (4):1974-80 [17279683.001]

[Cites] Chem Commun (Camb). 2005 Jan 7;(1):121-3 [15614393.001]

[Cites] Hum Mol Genet. 2006 Apr 15;15 Spec No 1:R95-101 [16651376.001]

[Cites] EMBO J. 2006 Oct 18;25(20):4952-62 [17024184.001]

[Cites] Nat Biotechnol. 2004 Nov;22(11):1360-1 [15529155.001]

[Cites] Anal Bioanal Chem. 2006 Oct;386(3):444-57 [16850295.001]

[Cites] Nat Rev Cancer. 2005 Nov;5(11):857-66 [16327764.001]

[Cites] Mol Cell. 1998 Oct;2(4):405-15 [9809062.001]

[Cites] Cell Cycle. 2004 Jul;3(7):836-9 [15190209.001]

[Cites] DNA Cell Biol. 2006 Feb;25(2):124-34 [16460236.001]

[Cites] Biochem Biophys Res Commun. 2005 Jun 10;331(3):761-77 [15865932.001]

[Cites] Biomed Pharmacother. 2005 May;59(4):139-42 [15862706.001]

[Cites] Chem Biol. 2005 Nov;12 (11):1227-34 [16298302.001]

[Cites] Nano Lett. 2006 Jul;6(7):1491-5 [16834436.001]

[Cites] Nat Chem Biol. 2006 Sep;2(9):474-9 [16862141.001]

[Cites] Oncogene. 2004 Apr 12;23(16):2797-808 [15077143.001]

(PMID = 17965848.001).

[ISSN] 0946-2716

[Journal-full-title] Journal of molecular medicine (Berlin, Germany)

[ISO-abbreviation] J. Mol. Med.

[Language] eng

[Publication-type] Journal Article; Research Support, Non-U.S. Gov't

[Publication-country] Germany

[Chemical-registry-number] 0 / Apoptosis Regulatory Proteins; 0 / Chromatin; 0 / Histones; 0 / RNA, Messenger; 0 / Tumor Suppressor Protein p53